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ABSTRACT
Interaction of the Human Serine Protease Inhibitor Alpha-1-antitrypsin
with Cryptosporidium parvum

by

John Russell Forney, Doctor of Philosophy
Utah State University, 1997
Major Professor: Dr. Mark C. Healey, DVM, PhD
Department: Biology
The human serine protease inhibitor (serpin) alpha-1-antitrypsin
(AAT) was studied for potential interaction with components of the
protozoan parasite Cryptosporidium parvum . A homogenate prepared from

C. parvum oocysts was incubated with purified human AAT, and complexes
formed between the serpin and components of the homogenate were detected
using an enzyme-linked immunosorbent assay (ELISA). Serpin:parasite
interactions were effectively blocked by preincubating AAT with a cognate
target enzyme, porcine pancreatic elastase, prior to performing the ELISA on
the homogenate. Incubation of a mixture of C. parvum oocysts and
sporozoites with AAT demonstrated preferential fluorescence labeling of the
sporozoite surface membrane by indirect immunofluorescence assay.
Localization of serpin complexes on sporozoites was confirmed by
immunogold electron microscopy.
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AAT was evaluated for in vitro anticryptosporidial activity in a bovine
fallopian tube epithelial (BFTE) cell culture system using both oocysts and
filter-purified sporozoites as inocula. Serial dilutions of AAT were mixed
with oocysts (or sporozoites) and used to inoculate BFTE cell monolayers.
Inoculated cells were maintained at 37°C / 5% C0 2 and collected at 24-, 48-, 72-,
and 96-hr post-inoculation intervals. The addition of AAT and other select
protease inhibitors (i.e., antipain, aprotinin, leupeptin, soybean trypsin
inhibitor, and phenylmethylsulfonyl fluoride) significantly inhibited parasite
infection (P <O.Ol) in a concentration- and time-dependent manner when
bleach-decontaminated oocysts were used in the inoculum.
The anticryptosporidial activity of AAT is postulated to be linked to an
antagonistic effect on oocyst excystation and, putatively, the forced
expenditure of bioenergetic reserves prior to host cell invasion. This
postulate was supported by the observations that serpin activity had no
statistically significant effect on reducing established in vitro infections (i.e.,
24 hr post-inoculation prior to addition of AAT) and did not inhibit infection
of BFTE cells when inoculated with sporozoite preparations. The combined
application of AAT and the aminoglycoside paromomycin demonstrated a
synergistic anticryptosporidial effect on in vitro infection and suggested the
basis for a multi-agent therapeutic protocol in preventing cryptosporidiosis.
These studies collectively demonstrated an anticryptosporidial potential for
serine protease inhibitors, in particular for AAT, and suggest an alternative
approach to conventional therapeutic strategies.

(175 pages)
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW

INTRODUCTION

In a span of less than 20 years, Cryptosporidium parvum has emerged
from the initial reports of human infection in 1976 to world-wide recognition
as an infectious agent of considerable morbidity in the AIDS patient
population. This enteropathogenic parasite invades the intestinal epithelium
and is capable of sustaining chronic patent infection in susceptible hosts, a
condition exacerbated by the present lack of efficacious therapy. Research
emphasizing a more thorough understanding of the parasite's developmental
maturation and efforts to identify strategies for chemotherapeutic
intervention are both timely and relevant.
This dissertation presents a succession of investigative studies that
have enhanced the collective knowledge of the cellular physiology and
immunobiology of C. parvum . The narrative is organized in a multiplepaper format supporting a common thematic focus; the functional interaction
between a human serine protease inhibitor (serpin), alpha-1-antitrypsin
(AA T), and the early developmental stages of the parasite. In addition to this
introduction, the first chapter reviews the literature and summarizes the
research objectives inherent to the studies presented in subsequent chapters.
The literature review is topically arranged and chronicles the relevant
findings of other investigators that influenced the current undertaking.
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Chapter 2 describes the initial study identifying an interaction between
AAT and C. parvum and provides an impetus for the evaluation of the in
vitro anticryptosporidial activity of AAT (Forney et al., 1996b). The discussion
section presents a hypothesized role for AAT in reducing the vulnerability of
host cells to parasite protease activity during the early stages of infection. The
implications of this study suggest several previously unexplored
characteristics of the immunobiology of C. parvum and potentiate an innate
defense mechanism against cryptosporidial infection in humans that is
mediated, at least in part, by intrinsic serpin activity.
Chapter 3 characterizes the functional significance of the interaction
between protease inhibitors and C. parvum. This chapter is based on the first
published report demonstrating a definitive association between proteolytic
activity and oocyst excystation and provides evidence of an antagonistic effect
by serine protease inhibitors on excystation (Forney et al., 1996c). Further, it
was demonstrated that C. parum expressed multiple proteolytic enzyme
activities during excystation; 1 protease component was inhibited by select
serine protease inhibitors and the other component was susceptible to
inhibition by the cysteine protease inhibitor L-trans-epoxysuccinylleucylamindo-( 4-guanidino )-butane (E-64).
Chapter 4 provides a thorough and systematic evaluation of the
antagonistic effect of AAT on oocyst excystation (Forney et al., 1997).
Experiments were performed to discern the influence of oocyst wall
permeability and the effect of inoculation source (i.e., oocysts or sporozoite)
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on AAT activity. Further, in vitro efficacy was monitored over extended
post-inoculation incubation periods and against established infections to
evaluate serpin activity against asexual intermediates of C. parvum. An
experimental protocol involved the reapplication of AAT at 24-hr intervals to
determine whether bioavailability had a significant impact on in vitro
activity. This final manipulation had no effect on in vitro efficacy, suggesting
that the biological availability of the serpin in cell culture was not a limiting
factor in its anticryptosporidial activity.
Chapter 5 incorporates a series of concise manuscripts (i.e., research
notes, short communications) derived from studies investigating the
anticryptosporidial potential of protease inhibitors in a bovine fallopian tube
epithelial (BFTE) cell culture system. The first section reports the use of
selected serine protease inhibitors to reduce C. parvum infectivity in BFTE
cells (Forney eta!., 1996a). The following section summarizes the results of
the initial in vitro study evaluating the anticryptosporidial activity of AAT
(Forney eta!., 1996d). The final section of Chapter 5 describes the synergistic
activity of AAT in combination with the aminoglycoside paromomycin. This
final note presents a strategy for chemotherapeutic intervention that includes
compounds targeting different developmental attributes of the parasite, such
as oocyst excystation and propagation of asexual intermediates.
Concluding remarks in Chapter 6 summarily review the relative
contributions of each of the individual studies and unify the collective results
in a final discussion of C. parvum excystation and infectivity. Speculation is
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made regarding the potential therapeutic application of protease inhibiting
compounds in treating chronic cryptosporidiosis, in both single and multiple
drug combinations. A final discussion includes recommendations for future
research efforts.

LITERATURE REVIEW

Cryptosporidium parvum
E. E. Tyzzer (1907) is acknowledged with the first published report of a
cryptosporidial organism when he described a sporozoan found in the peptic
glands of laboratory mice. He further detailed the characteristic morphology
and life-cycle stages of this parasite and established the basis for the species
description of Cryptosporidium muris (Tyzzer, 1910). Two years later Tyzzer
(1912) described a second species, C. parvum, in the small intestine of
laboratory mice. The next 50 years witnessed very little in the way of scientific
enlightenment regarding C. parvum; the parasite was generally considered to
be a commensal organism in the intestinal tract of vertebrate hosts. Various
reports of additional Cryptosporidium species were recorded during this
period, primarily based on an assumption of unique host specificity. The
majority of these reports have since been repudiated by cross-transmission
studies that define C. parvum as a multi-host parasite exhibiting little, if any,
host specificity (Current, 1986; Levine, 1986; Upton et al., 1989; Current and
Garcia, 1991; O'Donoghue, 1995).
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Levine (1986) systematically reviewed and updated the salient
characteristics of the genus Cryptosporidium and validated its taxonomic
classification in the phylum Apicomplexa, class Sporozoasida, order
Eucoccidiorida. Cryptosporidium spp. are further classified into the suborder
Eimeriorina based on their sexual reproductive stages (gamonts) and
nonmotile zygote (oocyst). The genus is the sole representative of the family
Cryptosporidiidae, distinguished by the presence of "free" sporozoites (i.e.,
lacking an intervening sporocyst) within the oocyst and the presence of an
attachment organelle ("feeder") at the base of the parasitophorous vacuole
(Johnson eta!., 1990; Cai et al., 1992).
In many respects, Cryptosporidium exhibits a similar pattern of
ontogeny to that observed in other coccidian genera, such as Eimeria and

Isospora, with a monoxenous (single host) life cycle (Fayer et a!., 1990;
O'Donoghue, 1995). However, it is the differences in propagation and host
cell infection that characterize this enigmatic parasite. The infective stage is
the oocyst, a small spherical to elliptical shaped form approximately 4-7 mm
in diameter, each one containing 4 sporozoites. Sporozoites excyst in the
lumen of the small intestine and invade the apical surface of epithelial cells
lining the microvilli. Within an intracellular, but extracytoplasmic,
parasitophorous vacuole, the sporozoite differentiates into a trophozoite and
undergoes multiple asexual reproduction (merogony) producing meronts
(Gobel and Brandler, 1982; Current, 1986; Rosales et al., 1992, 1993).
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The formation of an intramembranous vacuole by C. parvum appears
to be a unique evolutionary characteristic of this parasite. A thorough search
of the literature failed to reveal any phylogenetically related organism that
forms a similar developmental residence within an infected host cell. There
are many examples of microbial pathogens that occupy a more conventional
intracellular niche, within an intracytoplasmic vacuole. Such is the case for
obligate intracellular bacteria represented by the genera Shigella, Listeria,

Neisseria, and Vibrio as well as for the protozoan parasites Plasmodium and
Toxoplasma spp . The biochemical and molecular mechanism that fosters the
formation of the cryptosporidial parasitophorus vacuole is a confounding
puzzle to the parasitology community.
Two distinct types of meronts exist in the cryptosporidial life-cycle
(Vetterling et a!., 1971; Current, 1986; Fayer eta!., 1990; Ostrovska and Papema,
1990). The mature type I meront develops 8 merozoites that are released from
their intramembranous location and recycle the infection in the intestinal
epithelium. Type II meronts contain 4 merozoites that, upon release, infect
other intestinal epithelial cells and initiate a sexual reproductive cycle
(syngamy). Merogony amplifies parasite numbers and the type I meront can
putatively undergo multiple propagatory cycles before differentiating into the
type II meront stage. Separate macrogamonts and microgamonts develop
from type II merozoites, and microgametes are released to fertilize mature
macrogamonts (Gobel and Brandler, 1982). The resulting zygote undergoes
sporogony within the host epithelial cell and, upon maturation, is released
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into the intestinal lumen as a infective oocyst (Bird and Smith, 1980;
Yoshikawa and Iseki, 1992). Approximately 80% of the sporulated oocysts are
contained within a thick, multi-layered, environmentally resistant wall and
pass from the host in fecal excrement. The remaining oocysts are
characterized by a single, thin oocyst wall and are thought to excyst during
lumenal passage. Thin-walled oocysts perpetuate an autoinfective cycle in
the chronically infected host (Current, 1985; Current and Reese, 1986; Fayer et
a!. , 1990). In light of the multiple cycling of type I meronts and the
autoinfective potential of thin-walled oocysts, it is not difficult to visualize
the sustained 'proliferation of C. parvum that accompanies patent infection.
The role of surface adhesin molecules in the recognition and
attachment of C. parvum to the membrane of susceptible epithelial cells is
not clearly defined. Similarly, the sequence of biochemical and physiological
events that result in hypertrophy of microvilli at the site of parasite
attachment, fusion of extended microvillar membranes, and retention of the
parasitophorous vacuole within the host cell membrane is poorly
understood. Investigators have reported a putative role for surface-expressed
glycoproteins or lectin-associated membrane affinity to aid in the initial
attachment of C. parvum sporozoites to host cells (Bonnin et a!., 1991a, 1991b;
Tilley eta!., 1991; Petersen eta!., 1992; Thea eta!., 1992; Hamer eta!., 1994; Joe
eta!., 1994; Mitschler eta!., 1994; Tilley and Upton, 1994). The role of specific
receptor-ligand interactions between invasive C. parvum stages (i.e.,
sporozoites, type I and II merozoites, microgametes) and the host cell has not
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been thoroughly investigated. It is conceivable that cryptosporidial proteaselike components are involved in interactions at the host cell membrane level
such as has been demonstrated with related coccidians (Adams and Bushell,
1988; Fuller and McDougald, 1990). Bristow eta!. (1995) reported a cell surface
adhesion and fusion mechanism between the human immunodeficiency
virus and host cells that involved recognition between serine protease-like
receptors and corresponding structures analogous to serpin reactive sites. The
initial adherence of sporozoites to host cell membranes may facilitate the
spatial orientation of parasite proteases that further enhance cell attachment
and, potentially, contribute to the parasite's unique intramembranous
location within infected cells.
Panciera eta!. (1971) reported the initial incidence of disease associated
with C. parvum when he cited the parasite as the causative agent of diarrhea
in calves. Twenty-five years later, the literature abounds with reports of
diarrheal illness in many different animals attributed to C. parvum.
Veterinary medicine recognizes this protozoan as a significant etiology of
neonatal diarrhea in calves and lambs, with a concomitant economic impact
on the domestic animal industry. A multitude of reports, citing
cryptosporidiosis in 170 different animal species and a well documented
record of pathogenesis in over 50 countries worldwide, clearly expands
Tyzzer's initial description of a benign commensal to a ubiquitous enteric
pathogen (Fayer eta!., 1990; Current and Garcia, 1991; Powell, 1994).
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Human cryptosporidiosis
Despite the association between C. parvum and disease in animals for
over two decades, it was the initial reports of human cryptosporidiosis that
kindled the greatest spark of international scientific interest in the parasite.
In 1976, Cryptosporidium spp. was independently reported in two

immunocompromised patients as the primary etiology of profuse diarrhea
(Meisel et al., 1976; Nime et al., 1976). Reports of clinical illness from
cryptosporidiosis in both immunocompetent and immunocompromised
patient populations appeared intermittently in the medical literature over the
next decade. Ungar et al. (1990a) and Petersen (1992) have reviewed the
increased incidence of human cryptosporidiosis in the immunocompromised
host, a trend that parallels the rise in HIV infection noted in the mid-1980s
and persists in the current medical and scientific literature (Brandonisio et al.,
1993; Cotte et al., 1993; Georgiev, 1993; Goodgame et al., 1993, 1995; Moroni et
al., 1993; Giang et al., 1994; Mifsud et al., 1994; Molbak et al., 1994; Sorvillo et
al., 1994). The conclusive association between C. parvum infection and a
chronic, watery diarrheal illness in patients with AIDS has substantiated
interest in the immunology and biology of this protozoan (Current et al.,
1983; Tzipori, 1983; Casemore, 1990; Ungar et al., 1991; Gellin and Soave, 1992).
The epithelial lining of the microvilli in the small intestine is the
preferential site of parasite infection, and incubation periods ranging from 224 days are typically noted in human hosts (Tzipori et al., 1981a, 1981b;
Goodgame et al., 1995). The ensuing diarrhea is generally self-limited in an
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otherwise healthy individual with a spectrum ranging from asymptomatic,
subclinical cases to acute diarrhea, abdominal cramps and nausea of 1-3 wk
duration (Phillips eta!., 1992). Spontaneous eradication of the parasite from
the intestinal mucosa and protective acquired immunity is the general
outcome of infection in the immunocompetent individual. The most severe
consequence of human cryptosporidiosis occurs in the immunodeficient host.
These individuals frequently develop a profuse, protracted diarrheal illness
which progresses to a chronic patent infection exhibiting colonization of the
intestinal epithelium and, potentially, dissemination into the alveolar and
tracheal epithelium, stomach, pancreatic duct, and gall bladder (Garone et a!.,
1986; Ramsden and Freeth, 1989; Travis eta!., 1990; Petersen, 1992; Giang eta!.,
1994; Mifsud et a!. , 1994). Fluid loss from voluminous diarrhea can become
life-threatening for the chronically infected patient. This emerging clinical
scenario has established C. parvum as a significant opportunistic pathogen
and a cause of severe morbidity in susceptible patients (Davis et a!., 1987;
Kahn eta!., 1987; Petersen, 1992; Sun, 1994). Investigators have further
reported an association between severe cryptosporidiosis and profound
malnutrition that, if unresolved, results in a clinically apparent illness in
children closely resembling that seen in AIDS patients (MacFarlane and
Horner-Bryce, 1987; Sallon et a!., 1988; Kuhls et a!., 1992; Guarino et a!., 1993).
The underlying pathophysiology of cryptosporidial diarrhea is
unknown. Histologically, C. parvum infection is characterized by blunted,
fused microvilli in the small intestine with a concomitant crypt hyperplasia
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(Tzipori, 1983; McDonald and Bancroft, 1994; Goodgame et al., 1995; Moore et
a!., 1995). The voluminous, secretory nature of the resulting diarrhea,
frequently termed "cholera-like," suggests an enterotoxogenic etiology, but
studies have yet to define an operative agent (Brown et al., 1992; Chui and
Owen, 1994; Eggleston et al., 1994; Guarino et al., 1994).
Cryptosporidiosis has emerged dramatically as a significant water-borne
infection, best illustrated by the massive outbreak of cryptosporidiosis in
Milwaukee, Wisconsin in 1993 that totaled an estimated 403,000 cases of
infection (MacKenzie et al., 1994). In Milwaukee and related outbreaks, the
infective stage of the parasite (i.e., oocyst) has been recovered from treated
municipal water supplies (Peeters et al., 1989; Korich et al., 1990; Robertson et
al., 1992; MacKenzie et al., 1994; Aldom and Chagla, 1995). A growing body of
evidence suggests that cryptosporidial contamination of run-off water from
commercial livestock operations and human sewage treatment facilities
perpetuates a significant parasite reservoir in the environment (Jokipii et al.,
1985; Madore eta!., 1987; Current and Garcia, 1991; Hansen and Ongerth, 1991;
LeChevallier et al., 1991; MacKenzie et al., 1994). In both laboratory and
environmental settings, C. parvum oocysts demonstrate exceptional
resistance to chemical treatment and disinfection, particularly at those levels
of treatment determined to be safe for human consumption (Campbell et al.,
1982, 1993; Fayer et al., 1990; Fayer, 1994, 1995). The Centers for Disease
Control (1994) now consider cryptosporidiosis a major public health concern
for the United States and a significant emerging disease threat.

12
The severity and chronicity of human cryptosporidiosis is accentuated
by the present lack of clinically efficacious therapy and an incomplete
understanding of the immunobiology of the parasite (Flanigan and Soave,
1993; Moroni et al., 1993; Flanigan, 1994; O'Donoghue, 1995). Reports of
efficacious anticryptosporidial agents are largely based on anecdotal evidence
that has not been sustainable in controlled clinical trials (Wittenberg et al.,
1989; Zu et al., 1992; Flanigan and Soave, 1993). Additionally, in vitro
evidence of potential therapeutic efficacy against cryptosporidial infection has
not been successfully transferred to in vivo laboratory models or to infected
patients in a reproducible fashion (Wittenberg et al., 1989; Zu et al., 1992;
Flanigan and Soave, 1993; Verdon et al., 1994). Attempts to employ
conventional chemotherapeutic agents with established antimicrobial,
antifungal, or antiviral efficacy have not been consistently and reproducibly
successful in preventing or abrogating C. parvum infection in humans.
The immune status of the host appears to be the most significant
determinant of C. parvum infection severity. Predictably, immunotherapy
and immunological intervention highlight current research efforts to
develop an effective anticryptosporidial protocol. Intervention in the form of
passive oral transfer from hyperimmune colostrum and colostral derivatives
has shown encouraging results in the treatment of the immunocompromised
host (Mata, 1986; Tzipori et al., 1986; Ungar et al., 1990b; Plettenberg et al., 1993;
Shield et al., 1993). Lactogenic transfer, however, continues to be plagued by
an inconsistent clinical response and the inevitable recrudescence of infection
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following cessation of therapy (Tzipori, 1983; Moon eta!., 1988; Arrowood and
Sterling, 1989; Moody eta!., 1991; Tachibana eta!., 1991). Strategies to enhance
immune responsiveness with immunomodulating substances (i.e.,
dehydroepiandrosterone, azidothymidine, dialyzable leukocyte extracts) have
shown preliminary success in reducing the severity of infection and indicate a
potential route for continued therapeutic research (Chandrasekar, 1987;
Greenberg et a!., 1989; McMeeking et al., 1990; Rasmussen et al., 1992;
Rasmussen and Healey, 1992a, 1992b). Likewise, cryptosporidiosis in the
iatrogenically immunosuppressed host is frequently resolved once the
suppressive therapy is discontinued and immune responsiveness regains
normal efficacy (Miller et al., 1983; Foot et al., 1990).
The human immune response to C. parvum infection has been an area
of considerable research. Studies have demonstrated a significant humoral
response to C. parvum and have reported the production of antibodies
directed against antigens expressed in one or more developmental stages
(Taghi-Kilani et al., 1990; Fayer et al., 1991; Mosier et al., 1992; Nina eta!., 1992;
Georgiev, 1993; Moss eta!., 1994; Sorvillo et al., 1994). In vitro neutralization
of surface-expressed epitopes by both monoclonal and polyclonal antibodies
has been shown to reduce sporozoite and merozoite infectivity, implicating a
role for acquired antibodies in protection from repeated exposure (Riggs and
Perryman, 1987; Harp et al., 1989; Bjorneby eta!., 1990; Tilley et al., 1991; Uhl et
a!., 1992; Perryman et al., 1993; Tilley and Upton, 1994; Harp eta!., 1995). The
putative role of the cell-mediated immune system, and its various cytokine
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mediators, in the adaptive immune response to C. parvum has received
considerable attention in the literature. Reconstitution studies in nude and
SCID mice have shown an ameliorating effect on patent infection following
the adoptive transfer of human T lymphocytes, bone marrow cells, or cells of
lymph node origin (Mead et al., 1991; Whitmire and Harp, 1991; Harp et al.,
1992; Moss and Lammie, 1993; Cozon et al., 1994). Several studies have
shown that the depletion of differentiated effector cells such as NK cells, CDS
T lymphocytes, and CD4 T lymphocytes alters the course of infection in
laboratory models (Ungar et al., 1990b; Harp and Moon, 1991; Ungar et al.,
1991; Kuhls et al., 1992; Boher et al., 1994; McDonald et al., 1994; Mead et al.,
1994; Perryman et al., 1994). There is, however, evidence to suggest an
absence of measurable effects on resistance following selective depletion of
effector cells (Harp and Whitmire, 1991; Ungar et al., 1991; Rasmussen and
Healey, 1992b; Chen et al., 1993a; Harp et al., 1995). Reduced levels of
interferon gamma (IFN-y) and interleukin-2 (IL-2) have been shown to
contribute to enhanced murine infection (Ungar et al., 1991; Chen et al., 1993a,
1993b). Clearly, the mutual contributions of both the humoral and cellmediated adaptive immune responses are intimately associated with
eradication of cryptosporidial infection and formation of protective
immunity to subsequent challenge (Heyworth, 1990; Tachibana et al., 1991; Zu
et al., 1992; McDonald and Bancroft, 1994; Mead et al., 1994; Harp et al., 1995).
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It is also apparent that the immune response to cryptosporidiosis is a

complex, and largely unresolved, process.
Anecdotal evidence suggesting an age-related susceptibility to
cryptosporidiosis in humans most likely reflects a lack of immunologic
maturity of the host at the time of primary exposure (MacFarlane and
Homer-Bryce, 1987; Daoud eta!., 1990; Tangermann eta!., 1991; Kuhls eta!.,
1992). Notwithstanding the significance of underlying physiological changes
during the first several years of human development, it is probable that
maturation of the neonatal immune system accounts for the progressively
enhanced resistance to C. parvum infection observed in adolescence and
adults (Fripp eta!., 1991; Zu eta!., 1994).
The innate, nonspecific, nonadaptive defense mechanisms of the
human system are largely unexplored in regard to Cryptosporidium infection.
Reports of the beneficial effects of normal gut microflora in resisting C.

parvum infection in mice and the observation of anticryptosporidial activity
in nonimmune colostrum and bovine milk suggest that one or more
nonspecific factors, outside the parameters defined by the adaptive immune
response, potentially reduce host vulnerability and morbidity associated with

C. parvum infection (Brown eta!., 1992; Harp eta!., 1992; Garber eta!., 1994).
At present, the dynamics of early cryptosporidial infection and host defenses
against invasive stages of the organism are not fully understood.
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Alpha-1-antitrypsin
Alpha-1-antitrypsin (AAT) is a single chain glycoprotein composed of
394 amino acid residues with a molecular weight of approximately 56 kDa
(Travis and Salvesen, 1983). AAT is one of a group of human serine protease
inhibitors (serpin) found in peripheral circulation and tissue fluids.
Collectively, the serpin family provides intrinsic regulation of proteolytic
activity from endogenous proteases (Baumstark, 1967; Joslin et a!., 1993).
These inhibitors are particularly active during periods of acute inflammation
and are substantive components of the "acute phase" plasma protein
response elicited during the inflammatory process (Travis and Salvesen, 1983;
Carrell and Travis, 1985; Whicher eta!., 1993; Potempa eta!., 1994). In the
human system, AAT inhibits excessive protease-mediated tissue destruction
from neutrophil elastase and provides systemic protection from enzymatic
degradation in adjacent tissues (Cohen, 1975; Beatty eta!., 1980; Carrell, 1986;
Castellucci eta!., 1994).
The AAT glycoprotein undergoes a dramatic increase in hepatocellular
synthesis during acute inflammation. This episodic production is primarily
mediated by the cumulative interactions of interleukin-1 (IL-l) and
interleukin-6 (IL-6) and manifests itself in serum concentrations several
magnitudes greater than those observed in the normal, noninflammatory
state (Koj eta!., 1993; Perlmutter, 1993; Potempa eta!., 1994; Kanakoudi eta!.,
1995). While the primary source of systemic AAT is of hepatic origin,
increasing evidence supports the synthesis and release of supplemental AA T
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from extrahepatic sources. Reports of enhanced AAT synthesis in response to
inflammatory cytokines have been attributed to mononuclear cells from
peripheral circulation and intestinal epithelial cell lines in culture
(Perlmutter eta!., 1989, 1990; Molementi eta!., 1993). Perlmutter and his
colleagues (1989) first demonstrated the synthesis and secretion of AAT in
response to IL-6 stimulation in a human adenocarcinoma colonic epithelial
cell line (Caco-2). Molementi eta!. (1993) confirmed IL-6-induced AAT
production in the differentiated Caco-2 cell line and also measured AAT
synthesis in the undifferentiated enterocytic form of the Caco-2 cell line.
These investigators further demonstrated AA T synthesis in the human
intestinal epithelial cell line T84, another undifferentiated (crypt-like) cell
line, induced by the additive and synergistic action of IL-l and IL-6. These
findings potentiate an in vivo mechanism for AAT synthesis and secretion in
the human intestinal tract independent of crypt-to-villus differentiation.
Alpha-1-antitrypsin performs its inhibition action through the
formation of a 1:1 molecular complex with a serine protease (Baumstark,
1967; Carrell, 1986). The reactive site of AAT, Met358:ser359, interacts with
the active site of the target enzyme and blocks proteolytic activity by the
bound enzyme. In effect, AAT acts as a substrate analog for the cognate
enzyme. The serpin:enzyme complex (SEC) formed by the reactive site
interactions demonstrates high affinity in its binding association under
physiological conditions, primarily as a result of covalent attractions between
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the serpin and its cognate enzyme (Perlmutter eta!., 1990; Herve and Ghelis,
1991; Joslin eta!., 1993). The AAT reactive site loop imparts a degree of
functional specificity to the molecule; this portion of the molecule must
closely mimic the physiochemical properties of an appropriate substrate to
achieve serpin:protease recognition (Perlmutter, 1993). The SEC is rapidly
cleared from circulation and both molecules are physically eliminated from
further enzymatic activity (Carrell, 1986; Joslin eta!., 1993).
There is considerable evidence of a minor structural rearrangement of
the AA T molecule following complex formation with neutrophil elastase.
Cleavage of the complexed serpin at the methionine reactive site releases the
stressed configuration of the reactive site loop and exposes a small
(pentapeptide) sequence of the AAT protein (Perlmutter eta!., 1990; Joslin et
a!., 1991; Perlmutter, 1993). This exposed peptide fragment includes the
carboxyl terminal portion of the protein and has been attributed a functional
role in signaling upregulation of AA T synthesis in cells bearing a specific SEC
receptor (Perlmutter eta!., 1989). This mechanism of enhanced serpin
synthesis following inhibition of a target protease (i.e., elastase) and
recognition of the resulting complex by a SEC-specific receptor is a
homeostatically relevant mechanism in the balance of elastase and antielastase activity in humans. Additionally, the SEC possesses neutrophil
chemotactic properties and serves as an adjunct to other migration/attraction
signals expressed during inflammation or tissue injury (Travis and Salvesen,
1983; Banda eta!., 1988). Thus, the native AAT molecule demonstrates
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functionally specific inhibitory activity and the structurally altered molecule
in the SEC formation, specifically the carboxyl terminus associated
pentapeptide, exhibits a relatively broad range of biological effector properties
that enhance the process of inflammation in humans.
The literature contains very few previous examples of interactions
between AAT and parasitic pathogens. Lushbaugh et al. (1981) reported the
inhibition of Entamoeba histolytica cytotoxin, a proteolytic enzyme thought
to account for the amoeba's aggressive tissue invasion, by AAT and the alpha2-macroglobulin (A 2M) protein complex. A2 M and, to a lesser extent, AAT
were shown to inhibit tissue invasion of E. histolytica trophozoites. Further
analysis revealed the isolated protein cytotoxin-enterotoxin to be a cysteine
protease with a high sequence homology to papain-like enzymes; the trivial
name "amiebapain" has been suggested for the enzyme (Stanley et al., 1995).
Modha and Doenhoff (1994a) reported the formation of complexes
between human AAT and surface membrane components of Schistosoma
spp cercariae. Their results substantiate previous reports of serine protease
expression in schistosomes. The nature of the reported interaction,
presumably AAT binding to surface protease enzymes, suggests the basis for a
nonspecific host defense mechanism against exogenous protease activity
introduced by the invading schistosomule. The AAT:schistosome
interactions described by these investigators were further implicated as an
example of immune evasion by antigenic mimicry; the formation of AAT
complexes with surface-expressed parasite proteases blocks the

20
conformational availability of these immunogenic proteins to immune
effector cells. A parasite coated by host endogenous serpin proteins could
potentially evade host immune recognition (Modha and Doenhoff, 1994b).

Proteases in coccidian parasites
The role of natural and synthetic inhibitors in mediating the effects of
exogenous parasitic proteases is an area of active investigation. Key to this
research interest is the essential role of proteolysis in living cells and the
potential parasiticidal effects that could be achieved by interfering with
parasite protease at;tivity. Proteolytic activity has been described in the
invasion, infectivity, and pathogenicity of many parasitic pathogens.
Protease-mediated events facilitate host cell attachment (Arroyo and Aldrete,
1989), membrane penetration (Hadley et al., 1983; Adams and Bushell, 1988;
Fuller and McDougald, 1990), tissue migration (Modha et al., 1988; Modha and
Doenhoff, 1994a; Morris and Sakanari, 1995; Yenbuter and Scott, 1995), and
degradation of host proteins for use as a nutrition source (Chappell and
Dresden, 1986), and serve as a potential mechanism to elude host immune
responses (Marikovski et al., 1988; Malzels et al., 1993; Modha and Doenhoff,
1994b).
The majority of protozoan proteases described in the literature are of
the cysteine protease class (Coombs and North, 1991; North, 1992; McKerrow
et al., 1993). Serine protease activity has been demonstrated in several
parasitic species, but isolation and characterization of this class of enzymes
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have not been as frequently reported. Further, it is quite reasonable to
speculate that many protozoa may express multiple proteolytic enzymes of
various classes, either simultaneously or in a developmental-stage specific
fashion. A particularly difficult obstacle to overcome in working with
protozoan enzymes is the low levels of protein recovery from organisms and
the diverse number of life-cycle stages found in some species. Latency (i.e.,
expression of precursor enzyme forms) and autocatalytic properties further
hamper efforts to isolate and characterize enzyme activity.
Within the phylogenetic scheme Apicomplexa:Coccidia:Eucoccidiida,
protease enzyme identification and characterization have primarily focused
on Plasmodium spp. A number of malarial proteases have been described,
both by isolation as well as by the demonstration of proteolytic activity. The
initial report of protease activity in malaria appeared 50 years ago (Moulder
and Evans, 1946), and now over 15 distinct proteolytic enzymes have been
reported (reviewed in Coombs and North, 1991). Proteases have been
reported as critical factors in erythrocyte invasion / reinvasion (Rosenthal et
a!., 1987; McKerrow eta!., 1993), cell rupture (Bernard and Schrevel, 1987;
Grellier et a!., 1989), and hemoglobin degradation for nutrition (Sherman and
Tanigoshi, 1981, 1983; Rosenthal eta!., 1989). Of particular interest is the
report of a malarial protease that exhibits an inhibitor sensitivity pattern
suggesting serine and cysteine protease properties in a single enzyme
(Dluzewski et a!., 1986).
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Michalski eta!. (1994) isolated and partially characterized a serine
protease from homogenized sporulated Eimeria tenella oocysts. This study
cited the presence of both serine and cysteine protease activity in E. tenella
oocysts. Multiple proteases have been reported in a number of parasitic
genera, including Entameoba, Plasmodium, Tri cho monas , Trypana soma, and

Leishmania (McKerrow et a!., 1993). The phylogenetic relationship between
Eimeria and Cryptosporidium spp. suggests an analogous pattern of
proteolytic enzyme activity may exist in cryptosporidial oocysts.
Only recently has enzymatic activity been described in C. parvum .
Okhuysen et a!. (1994) demonstrated arginine aminopeptidase (AP) enzyme
activity associated with the sporozoite membrane and suggested a role for
aminopeptidase activity in facilitating oocyst excystation. Nesterenko et a!.
(1995) reported cysteine protease activity associated with solubilized
membrane fractions of excysted sporozoites and proposed an association
between enzyme activity and host cell infection. Inhibition of proteolytic
enzymes in coccidian parasites, notably in Eimeria spp and Plasmodium spp.,
by natural and synthetic serine protease inhibitors has shown a significant in
vitro reduction in cell infectivity (Hadley eta!., 1983; Adams and Bushell,
1988; Fuller and McDougald, 1990). It has now been shown that C. parvum
expresses protease activity, evidenced by azocasein hydrolysis, during peak
periods of excystation (Forney et a!., 1996c). Further, serine protease inhibitors
significantly antagonize excystation of oocysts and reduce in vitro infectivity
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(Forney eta!., 1996a, 1996d, 1997). Unlike Nesterenko's report of a cysteine
protease, cryptosporidial serine protease(s) has yet to be isolated and
characterized.

RESEARCH OBJECTIVES

The studies comprising this dissertation hypothesized the expression of
serine protease activity in one or more of the developmental stages of C.

parvum. It was further hypothesized that AAT, as the major serine protease
inhibitor in human circulation, could be an active component of an innate,
nonspecific defense mechanism against C. parvum infection. The specific
emphasis of these related postulates generated four research objectives:
1. Evaluate C. parvum for the expression of serine protease-like activity.

2. Determine if serine protease expression is a stage-specific characteristic of C.

parvum. If so, identify the developmental stage(s) that express serine
protease activity.
3.

Locate the site(s) of serpin complex formation on, or within, the C.

parvum organism.
4. Evaluate the in vitro anticryptosporidial potential of protease inhibitors.
These objectives represented an opportunity to expand the current
knowledge of the immunobiology of C. parvum and explore the relationship
between protease activity and infectivity. Localization of AAT interactions
with specific developmental stages of the parasite demonstrated the
expression of serine protease-like activity on the surface of freshly excysted
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sporozoites. Further, the capability of AAT, and other protease inhibitors, to
antagonize oocyst excystation and alter the infection dynamics of C. parvum
has provided a scientific basis to support the investigation of natural and
synthetic protease inhibitors as potential chemotherapeutic agents in the
treatment of cryptosporidiosis.
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CHAPTER2
INTERACTION OF THE HUMAN SERINE PROTEASE INHIBITOR
ALPHA-I-ANTITRYPSIN WITH CRYPTOSPORIDIUM PARVUM 1
ABSTRACT: The protozoan parasite Cryptosporidium parvum was

studied for interaction with a human serine protease inhibitor (serpin),
alpha-1-antitrypsin (AAT). A C. parvum homogenate (CPH) prepared from
oocysts was incubated with purified human AAT, and complexes formed
between the serpin and CPH were detected using an enzyme-linked
immunosorbent assay (ELISA). The optical density read at 450 nm of
AAT:CPH reactivity was significantly increased (P < 0.001) relative to CPH in
the absence of AAT treatment. Additionally, ELISA reactivity was blocked by
incubating AAT with a cognate target enzyme, porcine pancreatic elastase
(PPE), prior to treatment of the CPH. Incubation of a partially excysted sample
of C. parvum with AAT (37°C X 60 min) demonstrated preferential
fluorescence labeling of sporozoites by indirect immunofluorescence assay;
AAT complexes were not detected on intact oocysts. Localization of AAT
interactions with C. parvum sporozoites was visualized by transmission
immunoelectron microscopy. Collectively, these data suggest that C. parvum
sporozoites express a protease- like component that is recognized by human
AAT. The ability to block ELISA reactivity with PPE suggests that the AAT
interactions we detected are functionally similar to the serpin:enzyme
complex AAT forms with a protease target.
1Coauthored by J. R. Forney, 5. Yang, and M. C. Healey. 1996. Journal of Parasitology 82: 496502.
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INTRODUCTION

Cryptosporidium parvum (Apicomplexa: Cryptosporidiidae) is a
parasitic agent of diarrheal illness. This protozoan preferentially invades the
epithelial cells lining the microvilli of the small intestine and causes a
generally self-limited diarrhea in otherwise healthy individuals (Fayer et a!.,
1990). Spontaneous eradication of the parasite from the intestinal mucosa
and protective acquired immunity is the general outcome of infection in the
immunocompetent individual (O'Donoghue, 1995). The most severe
consequence of cryptosporidiosis occurs in the immunodeficient host. These
individuals frequently develop a profuse, protracted diarrheal illness which
progresses to a chronic patent infection of the intestinal epithelium (Gellin
and Soave, 1992; Phillips et a!., 1992) and, potentially, cryptosporidial
dissemination into the alveolar and tracheal epithelium (Petersen, 1992;
Giang eta!., 1994; Mifsud eta!., 1994).
Protease activity has been described in the invasion, infectivity, and
pathogenicity of several parasitic diseases. Protease-mediated events facilitate
host cell attachment (Adams and Bushell, 1988; Arroyo and Aldrete, 1989),
membrane penetration (Hadley eta!., 1983; Fuller and McDougald, 1990),
degradation of host proteins for use as a nutrition source (Chappell and
Dresden, 1986), tissue migration (Modha eta!., 1988; McKerrow eta!., 1990;
Modha and Doenhoff, 1994b; Morris and Sakanari, 1995; Yenbuter and Scott,
1995), and parasite maturation and development (Richer et a!., 1993), and
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provide a potential mechanism to elude host immune responses (Malzels et
a!., 1993; Modha and Doenhoff, 1994b).
Alpha-1-antitrypsin (AAT) is one of a group of human serine protease
inhibitors (serpin) found in peripheral circulation and tissue fluids.
Collectively, the serpin family provides an intrinsic defense mechanism to
regulate proteolytic activity from endogenous proteases (Baumstark, 1967;
Carrell and Travis, 1985; Joslin eta!., 1993). These inhibitors are particularly
active during periods of acute inflammation and are a substantive
component of the "acute phase" plasma protein response elicited during the
inflammatory process.

AAT undergoes a dramatic increase in hepatocellular

synthesis that manifests itself as serum concentrations several magnitudes
greater than normally present in peripheral circulation (Travis and Salvesen,
1983; Whicher et a!., 1993; Potempa et a!., 1994). In the inflammatory setting,
AAT inhibits excessive protease-mediated tissue destruction from leukocyte
elastase and provides systemic protection from enzymatic degradation in
adjacent tissues (Beatty et a!., 1980; Travis and Salvesen, 1983; Huber and
Carrell, 1989).
The specific objective of the present study was to examine C. parvum
for a serine protease-like component capable of recognition and functional
interaction with human AAT. Immunolocalization of the resulting
interactions was performed to determine if AAT-recognized protease-like
activity was expressed as a constitutive component of both oocysts and
sporozoites of C. parvum or if differential expression limited detection to
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only one of these stages. Here we report the detection of AAT complexes
formed with components of a cryptosporidial homogenate by an enzymelinked immunosorbent assay (ELISA). Further, a combination of indirect
immunofluorescence labeling and colloidal gold immunoelectron
microscopy localized AAT complexes on the sporozoite stage of C. parvum.
MATERIALS AND METHODS

Parasite propagation and isolation

Oocysts were maintained by passage in experimentally infected
Holstein calves and purified from feces using discontinuous sucrose and
isopycnic Percoll gradients (Arrowood and Sterling, 1987). Purified oocysts
were stored in 2.5% potassium dichromate (KzCrz07) at 4°C until used.
Oocysts, stored less than 90 days, were decontaminated with a 10% (v /v}
bleach solution for 10 min at 4°C and washed thoroughly with sterile Hanks'
balanced salt solution (HBSS) to remove residual bleach and KzCrz07.
Decontaminated oocysts were harvested following centrifugal concentration
and resuspended in sterile HBSS or phosphate buffered saline (PBS) prior to
use in assay protocols.
Preparation of parasite oocysts and
sporozoites

A mixture of intact oocysts and freshly excysted sporozoites was
prepared for use in immunolocalization assays. A purified suspension of C.
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parvum oocysts in PBS was allowed to excyst for 90 min (37°C /5% COz) in the
absence of any further treatment (Bonnin et a!., 1991; Robertson eta!., 1993).
Excystation efficacy was monitored by light microscopy. In some studies,
purified oocysts were freeze-thaw permeabilized prior to immunolabeling.
Preparation of parasite homogenate

A 5-ml suspension of

1Q6

oocysts / ml in 25 mM PBS was sonicated 5 X

45 seconds (50 mW) on ice to produce the C. parvum homogenate (CPH) used
in subsequent ELISA protocols. CPH prepared in this fashion was assayed for
total protein concentration (Bicinchonimic Acid Protein Assay, Pierce
Scientific, Rockford, Illinois) and typically yielded total protein values in the
range of 150-200 ~g/ ml. CPH was stored at -20°C prior to use.

ELISA

A modified ELISA was used to detect AAT interactions with CPH. A
100-Jll aliquot of CPH was added to test wells in 96-well flat bottom
polystyrene microtiter plates (Corning Glass Works, Corning, New York) in
the presence of a carbonate coating buffer, pH 9.4. Immobilization was
performed overnight at 4°C. Coated plates were washed with PBS / 0.05%
Tween 20 (PBST) and blocked with 1% gelatin / PBST for 4 hr at 25°C. The
blocked plates were washed with PBST and 100 Ill of a 50 Jlg/ ml dilution of
purified human AAT (Sigma Chemical Company, St. Louis, Missouri) was
added to each test well. The plates were incubated for 60 min at 37°C. The
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interaction between AAT and components of the immobilized CPH provided
a stabilized antigen for an indirect (2 antibody) ELISA (Crowther, 1995).
Subsequent steps were conducted at 37°C and were followed by PBST washing.
A 100-J.!l aliquot of 1:100 rabbit anti-human AAT, IgG fraction, (Sigma) was
added to test wells and incubated for 30 min. A 1:2000 dilution of horseradish
peroxidase (HRPO)-conjugated goat anti-rabbit IgG (Sigma) was then added to
test wells (100 Jll), followed by a 30 min incubation period. Plates were
washed a final time with PBST and 100 Jll of 4% 0-phenylenediamine (OPD)
dihydrochloride/0.02% hydrogen peroxide was added to each well. The plates
were then incubated for 10 min at 25°C and protected from light. Antibody
binding and ELISA reactivity was interpreted as an increase in optical density
measured at 450 nm (OD4so) (Microplate Autoreader, Bio-Tek Instruments,
Inc., Winooski, Vermont) relative to control wells containing immobilized
CPH, but untreated with human AAT. Variation between OD450 values was
examined for statistical significance utilizing 2-tailed t-test analysis and
simple analysis of variance (ANOVA) on a STATVIEWTM data analysis
program (Haycock eta!., 1992).
Blocking studies were performed using porcine pancreatic elastase
(PPE), a cognate target enzyme of AAT, to evaluate the functional specificity
of AAT complexes formed with components of CPH. PPE binds covalently to
the AAT molecule and occupies its reactive site loop, thereby eliminating the
potential for further inhibitor activity by the bound serpin (Joslin et a!., 1991,
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1993; Perlmutter, 1993). PPE was mixed with AAT in varying molar ratios
and the protease-serpin mixture was incubated 60 min at 37°C. The PPEtreated AAT was then added to gelatin-blocked, CPH-coated test wells and the
ELISA completed as described. OD450 values for PPE-blocked ELISA studies
were compared to AA T:CPH reactivity in the absence of PPE treatment for
statistically significance differences.
Immunofluorescence microscopy
A partially excysted mixture of oocysts and sporozoites was added to
each well of a

10-w~ll

immunofluorescence glass slide, air-dried at 25°C, and

heat-fixed. All subsequent steps were performed at 37°C in a humidity
chamber and separated by thoroughly washing with PBST. Each sample was
incubated successively in purified human AAT (50 J.tg/ ml X 60 min), rabbit
anti-human AAT, IgG fraction, (1 :100 X 30 min), and fluorescein
isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (1 :100 X 30 min).
Immunofluorescence assay (IFA) antibodies were obtained from Sigma.
Slides were again washed with PBST, covered with a nondrying mounting
medium, and examined by epifluorescence microscopy. Related studies
utilized freeze-thaw permeabilized oocysts as the initial sample with all
subsequent procedural steps identical to those described for the partially
excysted samples.
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Immunoelectron microscopy

Pre-embedding immunogold labeling: To emphasize surface labeling, a
mixture of intact oocysts and free sporozoites was fixed with 0.5%
glutaraldehyde in PBS at 4ac for 10 min and labeled as described by Sibley and
Sharma (1987) for transmission electron microscopy (TEM). In brief, the
lightly fixed parasites were washed in cold PBS and incubated successively in
human AAT (50 J.lg /ml X 60 min), rabbit anti-human AAT, IgG fraction (1:20
X 30 min), and 10 nm colloidal gold-conjugated goat anti-rabbit IgG (1:20 X 30
min) with each step separated by PBST washing at 4°C. Immunogold labeling
reagents were obtained from Sigma. Following the immunolabeling
procedure, parasites were fixed a second time in 0.5% glutaraldehyde at 4°C
for 20 min and dehydrated in an iced ethanol gradient. Samples were
impregnated with LR White resin (Electron Microscopy Sciences, Ft.
Washington, Pennsylvania) at 25°C and polymerized overnight at 60°C in
gelatin capsules. Thin sections of LR White-embedded samples were
mounted on nickel grids, carbon-coated, and viewed by TEM (Zeiss 902CEM,
Thornwood, New York) after contrast-enhanced staining with saturated
uranyl acetate (4 min at 50°C) and lead citrate (2 min at 25°C).

Post-embedding immunogold labeling: Samples of a C. parvum
excystation mixture were fixed with 0.5% glutaraldehyde/2%
paraformaldehyde in PBS at 4°C for 20 min. Fixed parasites were washed in
cold PBS, dehydrated in an iced ethanol gradient, and embedded in LR White
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resin. Thin sections were mounted on nickel grids, carbon-coated, and floated
for 10 min in PBS / 0.5"/o bovine serum albumin (BSA) / 0.02% Tween 20. The
samples were washed with PBST and transferred onto human AAT (50
!!g/ ml) for 60 min at 37°C. Grids were successively floated on rabbit antihuman AA T, IgG fraction (1:50 in blocking buffer) for 30 min and 10 nm
colloidal gold-conjugated goat anti-rabbit IgG (1 :20 in blocking buffer) for 30
min; each step was followed by PBST washing. After the final wash, grids
were rinsed with water and viewed by TEM after contrast-enhanced staining.

RESULTS

Detection of AA T interaction with
C. parvum
Figure 2-1 shows the pattern of ELISA reactivity observed for AAT
interactions with 3 different protein coatings, i.e., BSA, CPH, and PPE. ELISA
reactivity demonstrated a statistically significant increase (P < 0.001 ) in optical
density following incubation of the immobilized CPH with AAT relative to
immobilized CPH not exposed to AAT. The pattern of reactivity observed for
AAT-treated C. parvum was consistent with the increase in 00450 values
observed in reaction wells containing immobilized PPE as an initial antigen
coating. A concentration-dependent increase in 00450 was apparent
following AAT incubation with serial dilutions of CPH (Fig. 2-2). Figure 2-3
shows the blocking effect of PPE on serpin interaction with CPH. A loss of
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AAT:CPH reactivity (OD4so) was measured when AAT was incubated with
PPE (37°C X 60 min) before adding the serpin to ELISA test wells.

Immunolocalization of AA T:
parasite complexes

Indirect immunofluorescence labeling: A partially excysted mixture of
C. parvum oocysts and sporozoites, incubated with human AAT and
analyzed by an indirect IFA, demonstrated preferential labeling of the
sporozoite stage of the parasite (Fig. 2-4) . Sporozoites typically exhibited a
diffuse, moderately intense fluorescence pattern on their surface membrane.
Intact oocysts did not bind the FITC-conjugated ligand. Figure 2-5 illustrates
the immunofluorescence labeling pattern observed in freeze-thaw
permeabilized oocysts incubated with AAT. These samples revealed a
prominent fluorescence labeling of sporozoites within unexcysted, and
otherwise unlabeled, oocysts. Collectively, these observations show that AAT
interactions were limited to C. parvum sporozoites.

Immunoelectron microscopy: AAT interactions at the ultrastructural
level were investigated in thin sections of oocysts and sporozoites.
Immunogold labeling of C. parvum following incubation with AAT
demonstrated a prominent labeling of the surface of excysted sporozoites; a
smaller number of gold particles were observed in the intracellular matrix of
sectioned parasites (Fig. 2-6). As expected, the pattern of surface-associated
immunogold labeling was particularly well defined when samples were
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labeled prior to resin impregnation and polymerization. Post-embedding
labeling of sections through oocysts containing sporozoites showed gold
particles in association with the sporozoite stages, but in much smaller
numbers than observed for free sporozoites (Fig. 2-7). Surface-associated gold
labeling was typically uniform and evenly distributed on free sporozoites;
there was no discernible pattern of gold particles that would suggest a
differential gradient of AAT complexes on the sporozoite.

Cryptosporidium parvum oocysts did not bind the gold-conjugated
ligand in either the pre- or post-embedding labeling procedures, suggesting a
lack of AAT interaction with the oocyst wall. As seen in Figure 2-7, small
clusters of gold particles were occasionally observed within the perimeter wall
of unexcysted oocysts, but not in direct association with any structural
element of the internal oocyst wall.
DISCUSSION

This study is the first to demonstrate a functional interaction between a
human serpin (AA T) and components of the sporozoite stage of C. parvum.
This interaction, presumably the result of complexes formed between AAT
and parasite proteases, was detected by ELISA (Figs. 2-1, 2-2) and clearly
observed following IFA (Fig. 2-4). The complexes were further visualized by
TEM as a developmental stage-specific interaction primarily associated with
components of the sporozoite surface membrane (Fig. 2-6). Our findings, in
conjunction with Okhuysen et al.'s (1994) demonstration of arginyl
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aminopeptidase activity, suggest that C. parvum sporozoites express a serine
protease-like component that is functionally similar to trypsin (Powers et a!.,
1993). Classified in terms of substrate specificity, the anionic residues forming
the active site "pocket" of trypsin-like enzymes preferentially hydrolyze
peptides at cationic amino acid residues, such as arginine or lysine (Craik et
a!., 1985; Perona eta!., 1993; Powers eta!., 1993; Perona and Craik, 1995).
Whereas the preponderance of scientific evidence points to neutrophil
elastase as the primary physiologic target of AAT inhibition (Beatty et a!.,
1980; Gadek eta!., 1981; Huber and Carrell, 1989; Joslin eta!., 1993; Doring,
1994), the serpin molecule was originally described for its in vitro inhibitory
effect on trypsin (Mollet a!., 1958; Bundy and Mehl, 1959).
AAT is a single chain glycoprotein that performs its inhibitory action
through the formation of a 1:1 molecular complex with a serine protease
(Perlmutter, 1993). A reactive site loop of the AAT molecule interacts with
the corresponding active site of a target enzyme and blocks proteolytic activity
by the bound enzyme; in effect AAT acts as a substrate for the protease. The
serpin:enzyme complex (SEC) formed by the reactive site interactions
demonstrates high affinity in its binding association under physiological
conditions, primarily as a result of covalent attractions between the serpin
and its cognate enzyme. The AAT reactive site loop imparts a degree of
functional specificity to the molecule; this portion of the molecule closely
mimics the physiochemical properties of an appropriate substrate to achieve
serpin:protease recognition. Once formed, the SEC is rapidly cleared from
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circulation by specific receptor-mediated endocytosis in the parenchyma of the
liver (Perlmutter eta!., 1990; Joslin eta!., 1991).
The ELISA used in this study was designed to detect AAT:C. parvum
interactions by adapting the functional specificity of AAT to probe CPH for
protease-like components capable of interacting with the serpin molecule. To
achieve this end, we exploited 2 characteristics of the SEC. First, the AAT
molecule forms a very stable complex with a target enzyme Goslin et a!., 1993;
Stein and Carrell, 1995), stable enough to withstand the manipulations
accompanying the selected immunoassays. Second, SEC formation is
accomplished while retaining a relatively intact structural configuration of
the AAT molecule, thus permitting its detection by immunological
techniques directed against epitopes on that portion of the glycoprotein
protruding from the SEC Goslin eta!., 1991; Bjork eta!., 1993). The
demonstrated loss of ELISA reactivity following pretreatment of AAT with
PPE (Fig. 2-3) suggests that once elastase occupies the AAT reactive site loop, it
effectively blocks serpin recognition of analogous structures in the CPH.
The results of IFA and immunogold labeling show a clear distinction
in the labeling intensity between free sporozoites and sporozoites within
intact oocysts. Figure 2-6 illustrates a qualitatively enhanced recognition of
AAT complexes on freshly excysted sporozoites compared to unexcysted
sporozoites within otherwise intact oocysts (Fig. 2-7). We postulate that
serine protease-like components of C. parvum sporozoites are in an
enzymatically inactive form prior to excystation. In the zymogen
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(proenzyme) form, protease activity would remain at very low levels until
activated by one or more conditions that "trigger" excystation. Okhuysen et
a!. (1994) described enhanced aminopeptidase activity after prolonged
incubation in conditions favorable to excystation; similarly, we demonstrated
a qualitatively greater detection of AAT complexes formed with excysted
sporozoites (Fig. 2-4) and in permeabilized oocysts following incubation with
AAT at 37°C (Fig. 2-5). Because AAT binds to the active site of a target
enzyme, SEC formation favors the enzymatically active form of proteases
(Perlmutter, 1993; Perona eta!., 1993; Perona and Craik, 1995).
The lack of immunolabeling associated with intact oocysts indicates a
lack of AAT interaction with the oocyst wall and implies an absence of serine
protease-like expression on this stage of parasite development. We did
observe some oocyst sections that contained a small number of gold particles
within the confines of an intact oocyst wall (Fig. 2-7). This observation may
reflect the dissociation of AA T complexes from sporozoites as an artifact of
the fixing, sectioning, and labeling process. Conversely, intraoocyst gold
conjugate may indicate that metabolically active sporozoites undergo lowlevel expression and shedding of protease-like components while sequestered
within an intact oocyst.
There is substantial evidence of a structural rearrangement of the AA T
molecule following complex formation with a protease target that presents a
small (pentapeptide) sequence of the AAT protein (Perlmutter eta!., 1990;
Perlmutter, 1993; Stein and Carrell, 1995). This exposed peptide fragment
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includes the carboxyl terminal sequence of the protein and has been attributed
a functional role in signaling upregulation of AAT synthesis in cells bearing a
specific SEC receptor (Schreiber and Aldred, 1993; Perlmutter, 1993; Potempa
et a!., 1994). We speculate that a protease-like component expressed by C.
parvum sporozoites may help upregulate AAT levels mediated by specific

receptor recognition of SEC complexes. Though lacking parasite specificity,
this primitive defense mechanism may afford protection against proteolytic
activity during the course of early infection and minimize host vulnerability
to exogenous proteases while an adaptive immune response is being
mounted against the parasite. An interesting association is apparent given
the in vitro demonstration of an "acute phase" protein response in
extrahepatic sites (Molementi eta!., 1993; Perlmutter, 1993). These
observations, in particular Molementi's demonstration of AAT production in
human intestinal epithelial cells, suggest the possibility of a self-amplifying
serpin response to cryptosporidial proteases sustained by upregulation of
AAT synthesis in the immediate vicinity of parasitic infection. While the
potential for local (i.e., intestinal epithelium) AAT production may exist as a
homeostatic response to exogenous proteases, a recent study reported a lack of
correlation between the intensity of cryptosporidial infection and fecal AAT
clearance (Goodgame eta!., 1995). The influence of extrahepatic AAT
production in intestinal parasitic infections is yet to be fully defined.
The role of protease inhibitors in abrogating the effects of exogenous
parasite proteases is an area of active investigation. This class of regulatory
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proteins has been reported to reduce intraerythrocytic stages of Plasmodium

vinckei in mice (Rosenthal et al., 1993); affect the maturation and
development of Trypanosoma spp (Meirelles et a!. , 1992), Strongyloidies

stercora/is (McKerrow eta!., 1990), and Dirofilaria immitis (Richer et a!., 1993);
and reduce the in vitro infectivity of Eimeria spp (Adams and Bushell, 1988;
Fuller and McDougald, 1990; Cohen eta!., 1991). Modha and Doenhoff (1994a)
reported the formation of complexes between human AAT and surface
membrane components of Schistosoma spp cercariae. Their data suggest a
putative role for human serpin activity during schistosoma! infection. The
nature of the reported interaction, AAT binding to parasite proteases, suggests
that a nonspecific defense mechanism against exogenous parasite proteases
facilitates the homeostatic balance between protease and anti-protease activity.
Modha and Doenhoff further suggested (1994b) that schistosome interactions
with circulating serpin molecules are an example of immune evasion by
antigenic mimicry. The formation of AAT complexes with surface-expressed
proteases blocks the conformational availability of these immunogenic
parasite proteins to immune effector cells. A foreign organism coated by
endogenous host serpin proteins could potentially evade immune
recognition.
Bristow et a!. (1995) recently demonstrated a cell surface adhesion and
fusion mechanism between a viral pathogen and host target cells involving
recognition between serine protease-like receptors and corresponding
structures analogous to serpin reactive sites. The search for comparable
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surface adhesins with regard to C. parvum recognition of host epithelial cells
and subsequent membrane fusion may elucidate the early invasion sequence
of this parasite. It is conceivable that cryptosporidial protease-like
components are involved in interactions at the host cell membrane level
such as has been demonstrated with related coccidians (Adams and Bushell,
1988; Fuller and McDougald, 1990). Several investigators have reported a
putative role for surface-expressed glycoproteins or lectin-associated
membrane affinity to aid in the initial attachment of C. parvum sporozoites
to host cells (Bonnin et al., 1991; Tilley et al., 1991; Petersen et al., 1992;
Mitschler et al., 1994; Tilley and Upton, 1994). The initial adherence of
sporozoites to host cell membranes may facilitate the spatial orientation of
parasite proteases that further enhance cell attachment and, potentially,
contribute to the parasite's unique intramembranous location within infected
cells.
This study demonstrated a functional interaction between human
AAT and a protease-like component of the initial invasive stage of C.

parvum, the sporozoite. This interaction was predominately associated with
the outer surface of excysted sporozoites; AA T complexes were not detected
on either the internal or external surface of the oocyst wall. These findings
suggest that the putative role of human AAT in regulating exogenous
protease activity should include a protease-like component expressed by C.

parvum. It would be of particular interest to evaluate the anticryptosporidial
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potential of serpin compounds by studying the effects of AAT on C. parvum
infection in permissive cell culture systems and laboratory animal models.
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Figure 2-1. Pattern of ELISA reactivity for alpha-1-antitrypsin interactions
with 3 different coating proteins. Cryptosporidium parvum homogenate
(CPH), porcine pancreatic elastase (PPE), and bovine serum albumin (BSA)
were used to coat ELISA test wells prior to incubation with alpha-1antitrypsin (AAT). ELISA reactivity for wells coated with CPH and PPE was
significantly greater (P < 0.001) than values determined for untreated wells
and for the BSA control. The data reflect 2 experiments containing a total of 4
replicates of BSA and 12 replicates each for wells coated with CPH and
elastase. Data are presented as the mean± SD.
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Figure 2-2. Concentration-dependent reactivity of alpha-1antitrypsin:Cryptosporidium parvum homogenate interactions. OD450
values for AAT:CPH (-• -) increased proportional to increases in the
concentration of CPH [total protein]. Controls consisted of CPH without
exposure to AAT, treated with either phosphate buffered saline (-o-) or 2%
(w / v) bovine serum albumin (-• -) in place of the serpin. The data represent
2 experiments of 2 replicates each for control values and 4 replicates each for
AAT treatment of CPH. Data are presented as the mean± SD.
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Figure 2-3. Effects of porcine pancreatic elastase pretreatment of alpha-1antitrypsin on ELISA reactivity. Blocking was demonstrated by pretreating
AAT with PPE prior to incubation of C. parvum homogenate (CPH) (-e-).
OD450 values for AAT:CPH reactivity decreased in response to an increase in
the ratio of [PPE] to [AAT] . Test wells containing bovine serum albumin
(BSA) as a coating antigen (-D-) were unaffected by PPE blocking.
Substituting phosphate buffered saline (PBS) for PPE in the pretreatment step
(-o-) resulted in a slower loss of ELISA reactivity, suggesting a dilution effect
on [AAT]. The data reflect 2 experiments of 4 replicates for each test well
containing CPH and duplicate values for the BSA control. Data are presented
as the mean ± SO.
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Figure 2-4. Indirect immunofluorescence microscopy of alpha-1-antitrypsin
interactions with Cryptosporidium parvum. Uniform fluorescence labeling
was evident on the surface of excysted sporozoites following AAT exposure
(arrow). Note the absence of FITC-conjugated ligand on the oocyst wall
(arrowhead) . Scale bar= 10 IJ.m.
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Figure 2-5. Irnrnunolabeling of perrneabilized oocysts. Freeze-thaw
perrneabilized oocysts incubated with AAT were permissive to
immunolabeling of serpin complexes formed with sequestered sporozoites
(arrow); the oocyst wall remained refractory to AAT interaction. Scale bar=
10

~m .
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Figure 2-6. Transmission immunoelectron micrograph of Cryptosporidium

parvum sporozoites following incubation with alpha-1-antitrypsin.
Immunodetection of AAT interactions with C. parvum at the ultrastructural
level is shown by the dense gold labeling on the surface of excysted
sporozoites. Scale bar

=350 IJ.m.
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Figure 2-7. Transmission electron micrograph of alpha-1-antitrypsin
interactions with encysted Cryptosporidium parvum sporozoites. An
ultrathin section of an intact oocyst containing longitudinal and transverse
sections through the sporozoites is observed. A minimal number of gold
particles are seen on the sectioned sporozoites following incubation with
AAT (arrow). A few small clusters of gold particles are present within the
confines of the oocyst wall (arrowhead), suggesting the low-level secretion of
a protease-like component by sequestered sporozoites or shedding of the
serpin:enzyme complex during labeling. Scale bar= 235 Jlm.
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CHAPTER 3
PROTEASE ACTIVITY ASSOCIATED WITH EXCYSTATION OF

CRYPTOSPORIDIUM PARVUM OOCYSTS 1
ABSTRACT: A Cryptosporidium parvum homogenate (CPH),

prepared from partially excysted oocysts, was examined for proteolytic activity
capable of hydrolyzing azocasein. Protease activity, measured at pH 7.0, was
not detected in fresh oocysts, but increased progressively with incubation at
37°C. Activity peaked after 60 min incubation, but progressively decreased
with extended incubation intervals. Cryptosporidial protease activity was
significantly inhibited (P < 0.01) by the serine protease inhibitors
phenylmethylsulfonyl fluoride (PMSF), diisopropyl fluorophosphate (DIFP),
aprotinin, alpha-1-antitrypsin (AAT) and the cysteine protease inhibitor Ltrans-epoxysuccinyl-leucylamindo-(4-guanidino)-butane (E-64). No single
inhibitor completely blocked CPH-associated protease activity; however, the
combination of PMSF and E-64 inhibited >95% of the azocasein hydrolysis
measured in untreated control samples. The same group of inhibitors were
further evaluated for their ability to inhibit excystation of C. parvum oocysts.
PMSF, DIFP, aprotinin, and AAT significantly inhibited (P < 0.05) oocyst
excystation at 15-, 30-, and 60-min incubation intervals; E-64 had no
significant inhibitory effect on excystation. The results of this study
demonstrate proteolytic activity during peak periods of excystation. Further,
we showed that cryptosporidial protease activity was sensitive to both serine
and cysteine protease inhibitors, but only serine protease inhibitors

'Coauthored by). R. Forney, 5. Yang, and M. C. Healey. 1996. journal of Parasitology 82: 889902.
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significantly inhibited oocys t excystation. These findings provide preliminary
evidence of cryptosporidial proteases of both serine and cysteine protease
classes and suggest that serine protease(s) are functionally associated with
excystation.

INTRODUCTION

Cryptosporidium parvum (Apicomplexa: Cryptosporidiidae) is a
protozoan parasite that preferentially invades epithelial cells lining the
microvilli of the small intestine (Payer et a!., 1990; O'Donoghue, 1995). The
most severe consequence of human cryptosporidiosis occurs in the
immunodeficient host; C. parvum is an opportunistic pathogen of substantial
morbidity in the acquired immunodeficiency syndrome (AIDS) patient
population. The immunocompromised host develops a profuse, watery
diarrheal illness which may progress to a chronic, patent infection of the
intestinal epithelium (Gellin and Soave, 1992; Goodgame eta!., 1995). The
chronicity and severity of cryptosporidiosis are accentuated by the lack of
therapeutic agents capable of eradicating the parasite.
The infective stage of C. parvum is the oocyst, a thick-walled, doublelayered structure containing 4 sporozoites. The intact oocyst is particularly
resistant to environmental stress, chemical disinfectants, and many
municipal water purification processes (Campbell et a!., 1982, 1993; MacKenzie
et a!., 1994; CDC, 1995). Sporozoites excyst from the oocyst following ingestion
and attach to the intestinal microvilli; parasite development proceeds within
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an enigmatic residence, an intracellular, but extracytoplasmic,
parasitophorous vacuole. A small proportion (approximately 20%) of the
oocysts produced in an infected host are ensheathed within a thin, single
layer outer wall. This thin-walled oocyst undergoes endogenous sporulation
and rapidly excysts in the intestinal lumen, accounting for the autoinfective
cycle observed in chronically infected hosts (Current and Garcia, 1991; Chui
and Owen, 1994; O'Donoghue, 1995). The characteristics of early
cryptosporidial infection, including excystation, are an area of active
investigative effort. Studies have identified conditions that favor excystation
and reported protocols to optimize in vitro sporozoite production (Robertson
eta!., 1992, 1993; Upton eta!., 1994); however, the biochemical processes that
facilitate the emergence of sporozoites from an infective oocyst remain largely
undefined .
Recently, investigators have described arginyl aminopeptidase activity
(Okhuysen eta!., 1994) and a putative cysteine proteinase (Nesterenko et a!. ,
1995), both associated with the outer membrane of sporozoites. Our previous
study detected an interaction between the human serine protease inhibitor
alpha-1-antitrypsin (AAT) and the surface of excysted sporozoites (Forney et
a!. , 1996b). Additionally, we have demonstrated a significant
anticryptosporidial potential for selected protease inhibitors, including
human AAT, in a bovine fallopian tube epithelial (BFTE) cell culture system
(Forney et a!., 1996a). Collectively, emerging evidence suggests that
cryptosporidial protease / peptidase activity is requisite for C. parvum
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excystation and the initial d ynamics of host cell infection. Speculation on the
role of endogenous proteolytic enzymes during excystation prompted the
present study to evaluate C. parvum for protease activity associated with peak
periods of oocyst excystation. Further, our objectives included a study of the
effects of selected inhibitors on parasite protease activity and oocyst
excystation.

MATERIALS AND METHODS

Parasite propagation and isolation
Oocysts were maintained by passage in experimentally infected
Holstein calves, purified from feces using discontinuous sucrose and
isopycnic Percoll gradients (Arrowood and Sterling, 1987), and stored in 2.5%
potassium dichromate (K2Cr207) at 4°C. Oocysts were decontaminated in
10% (v /v) bleach for 10 min at 4°C and washed thoroughly with sterile
Hanks' balanced salt solution (HBSS) to remove residual bleach and K2Cr207.
Decontaminated oocysts were harvested following centrifugal concentration
and resuspended in sterile RPMI medium (HyClone Laboratories, Inc., Logan,
Utah).

Excystation studies
Aliquots of purified oocysts were added to sterile plastic
microcentrifuge tubes and intact oocysts were counted in a hemacytometer
using phase contrast microscopy. Oocysts were then incubated at 37°C in the

76
absence of any further treatment (Bonnin eta!., 1991; Robertson eta!., 1993;
Upton et a!., 1994). Tubes were removed from the incubation environment at
fixed time intervals, i.e., 15, 30, 60, 90, 120, and 180 min, and intact oocysts
were again enumerated (excluding empty oocyst "ghosts" and partiallyexcysted oocysts) . The difference between the number of oocysts counted
prior to incubation and the number of oocysts counted after incubation was
expressed as a percent of the original, i.e., pre-incubation, number. This value
was termed "percent of excystation" and represented an indirect assessment of
excystation.
Preparation of parasite homogenate

Bleach-treated oocysts were incubated at the timed intervals indicated
previously and then snap frozen in liquid nitrogen to suspend further
excystation. These partially excysted mixtures of oocyst and sporozoite forms
were thawed in a 37°C water-bath and sonicated 6 X 45 seconds (50 mW) on
ice to produce a C. parv um homogenate (CPH). Samples of the resulting
sonicate were examined by light microscopy to ensure that CPH was free of
intact oocysts and sporozoites. Peak protease activity was observed in
homogenates prepared from oocyst incubated for 60 min; for subsequent
inhibitor sensitivity studies, a 3-ml suspension of 106 oocysts/ml in RPMI
medium was incubated at 37°C for 60 min and sonicated as before. CPH
prepared in this fashion was assayed for total protein concentration
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(Bicinchoninic Acid Protein Assay, Pierce Scientific, Rockford, Illinois) and
the final total protein concentration was adjusted to 200-250 !!g/ ml.

Assay for proteolytic activity
Azocasein (Sigma Chemical Company, St. Louis, Missouri) was used as
a substrate in a microassay protocol for proteolytic activity (Plantner, 1991). In
brief, 200 111 aliquots of a 2 mg /ml solution of azocasein in 100 mM sodium
phosphate buffer, pH 7.0, was prewarmed 15 min at 37°C. Evaluation of
protease activity was confined to pH 7.0, consistent with the neutral
excystation environment used in this study. A 50-!!1 aliquot of CPH was
added to each tube and the reaction mixture was incubated at 37°C for 10 hr.
Following incubation, 40-!!1 of 50% cold trichloroacetic acid (TCA) was added
to each tube to precipitate undigested azocasein and tubes were placed on ice
for 60 min. The reaction solution was clarified by centrifugation (7,000 g for
10 min). A 200-!!1 aliquot of the reaction supernatant was added to individual
wells in a 96-well microtiter plate; each well contained 20 111 of 10 N NaOH.
The absorbance of the alkalinized solution was read at 450 nm (A4so) in an
automated microtiter plate reader (Microplate Autoreader, Bio-Tek
Instruments, Inc., Winooski, Vermont). Diluted commercial trypsin (Type
IV; Sigma) was used as a control for casein hydrolysis.

78
Protease inhibitors
The protease inhibitors alpha-1-antitrypsin (AAT; Chemicon
International, Inc., Temecula, California), aprotinin (ICN Biochemicals, Inc.,
Aurora, Ohio), L-trans-epoxysuccinyl-leucylamindo-(4-guanidino)-butane (E64; Sigma), diisopropyl fluorophosphate (DIFP; Sigma), and
phenylmethylsu!fonyl fluoride (PMSF; Sigma) were evaluated for their effect
on CPH-associated protease activity and oocyst excystation. Dilutions of AAT
and aprotinin were prepared in 10-Jlg/ ml and 100-Jlg/ml concentrations in
sterile 25 mM phosphate-buffered saline (PBS); DIFP, E-64, and PMSF were
first dissolved in dimethyl sulfoxide (DMSO; Sigma) and subsequently diluted
to 1-mM and 10-mM concentrations in PBS. Inhibition studies involved the
pre-incubation of equal volumes of CPH and protease inhibitors for 30 min at
25°C prior to assay with azocasein. The differences in A450 values for
inhibitor-treated CPH samples and untreated control samples (similarly
diluted) were compared for statistical significance using ANOV A (Fisher's
PLSD).
To evaluate the effect of protease inhibitors on excystation, purified
oocysts were mixed with equal volumes of protease inhibitor solutions and
subjected to the excystation conditions previously described. The number of
oocysts that excysted in inhibitor-treated groups was expressed as a percent of
the number of oocysts excysted in untreated control samples. Inhibitors
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requiring preparatory dissolution in DMSO were matched with excystation
controls containing equal concentrations of DMSO.

RESULTS
Excystation studies
Under standard conditions (37°C, RPMI medium) excystation increased
rapidly during the initial 90 min (Fig. 3-1). The percent of excystation at 120
(74.5 ± 1.41) and 180 (76.7 ± 2.12) min was increased over shorter incubation
times, but did not significantly differ from the percent of excystation at 90 min
(68.5 ± 1.06). In effect, 89.3% of the total excystation observed occurred within
the first 90 minutes of incubation, with 78.2% occurring within the first 60
min .
Table 3-1 shows the effects of selected protease inhibitors on the
excystation dynamics of C. parvum oocysts. The serine protease inhibitors
PMSF, DIFP, aprotinin, and AAT significantly inhibited excystation (P < 0.05)
in the sampling intervals from 15 to 60 min, but the percent of excystation
obtained at 90-180 min was not significantly reduced below control levels by
any of the pro tease inhibitors we evaluated. PMSF, at a concentration of 10
mM, was the most potent excystation inhibitor evaluated. The cysteine
protease inhibitor E-64 had no significant inhibitory effect on excystation.
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Protease activity

Protease activity was detected in CPH prepared from oocysts incubated
at 37°C. Figure 3-1 shows the relationship between azocasein hydrolysis
(A4so) and the length of time oocysts were incubated prior to
homogenization. Protease activity was absent in unincubated oocysts;
azocasein hydrolysis increased with oocyst incubation time, and peak activity
was measured in CPH prepared from oocysts that were incubated for 60 min.
Azocasein hydrolysis progressively declined in CPH prepared from oocysts
incubated for 90- to 180-min intervals.
Inhibitor sensitivity studies were conducted on CPH prepared from
oocysts that had been incubated for 60 min to coincide with the period of
highest hydrolytic activity. Cryptosporidial protease activity was significantly
inhibited (P < 0.05) by the serine protease inhibitors PMSF, DIFP, and AAT at
each of the concentrations evaluated (Table 3-2). Aprotinin significantly
inhibited azocasein hydrolysis (P < 0.05) when tested at a concentration of 100
Jlg/ml; a 10-Jlg/ml concentration of aprotinin had no significant effect on
protease activity. The cysteine protease inhibitor E-64 significantly inhibited
(P < 0.05) azocasein hydrolysis at concentrations of both 1 mM and 10 mM.

The combination of 10 mM PMSF and 10 mM E-64 inhibited 95.8% of the
hydrolytic activity measured in unchallenged control samples.
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DISCUSSION

This study reports the detection of proteolytic activity in homogenates
prepared from C. parvum oocysts collected during peak periods of excystation.
CPH-associated protease activity paralleled the increase in excystation
observed with incubation of oocysts at 37°C (Fig. 3-1). Our findings showed
that protease activity peaked at the 60-min incubation interval and steadily
declined when oocysts were incubated for longer periods. Further, this study
suggests that CPH contained proteases sensitive to both serine and cysteine
protease inhibitors.
The pattern of oocyst excystation observed in this study is consistent
with previous reports of excystation dynamics. Upton eta!. (1994) reported a
high rate of excystation during the initial 90 min of incubation at 37°C in
RPMI medium. Whereas our study did not attain as high a percent of
excystation as reported by those authors, the rapid rate of excystation we
observed in the 15- to 90-min intervals is in substantial agreement.
Robertson eta!. (1993) recommended a protocol for in vitro excystation that
limited oocyst incubation to 30 min at 37°C to maximize sporozoite viability.
In vitro studies strongly suggest that sporozoite viability, and subsequent

infectivity, is optimally associated with the peak excystation period occurring
during the initial 30-90 min of incubation at 37°C.
As seen in Table 3-1, the pattern of excystation inhibition (inhibition by
PMSF, DIFP, aprotinin, and AAT; lack of inhibition by E-64) strongly suggests
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that a C. parvum serine protease(s) is functionally associated with excystation.
Michalski et al. (1994) reported similar findings in a homogenate prepared
from sporulated Eimeria tenella oocysts. Their study detected a mixed
inhibitor sensitivity pattern indicative of the presence of both serine and
cysteine proteases in E. tenella oocysts.
The findings of this study suggest that C. parvum oocysts may also
contain multiple proteases with inhibitor sensitivities characteristic of both
the serine and cysteine protease classes. Nesterenko et al. (1995) reported a
cysteine protease detected in solubilized sporozoite membranes. Because the
homogenate used in the present study contained components of both oocysts
and sporozoites, the E-64-sensitive component of CPH may represent the
cysteine protease previously described. The potential expression of multiple
proteases in a crude homogenate of C. parvum is certainly not an unexpected
finding in protozoans. Multiple proteases have been reported in a number of
parasitic genera, including Entameoba , Plasmodium , Trichomonas,
Trypanasoma , and Leishmania (McKerrow et al., 1993) Alternately, there is

evidence of a malarial protease that exhibits an inhibitor sensitivity pattern
suggesting serine and cysteine protease properties in a single enzyme
(Deguercy et al., 1990).
Our previous study reported an interaction between human AAT and

C. parvum (Forney, 1996b). The localization of AAT complexes on the
external surface of excysted sporozoites suggested the expression of a proteaselike component on this early developmental stage of the parasite. The
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present study supports this hypothesis by demonstrating proteolytic activity
and showing the antagonistic properties of serine protease inhibitors on
excystation. The mechanism by which serine protease inhibitors block
excystation is not fully understood. It has been shown that bleach treatment
increases the permeability of the oocyst wall and enhances excystation
(Reduker and Speer, 1985; Robertson et al., 1993). Our use of bleach to
decontaminate oocysts may have provided a means for inhibitors to penetrate
the oocyst wall and inhibit intra-oocyst proteases. We have not evaluated the
effect of serine protease inhibitors on excystation of unbleached oocysts.
The observation that inhibitor-treated oocysts eventually approached
control levels of excystation after 90-180 min incubation suggests that
excystation is only partially blocked by the inhibitors and concentrations
evaluated in this study. The half-life of some inhibitors, such as PMSF and
DIFP, is relatively short and loss of inhibitory effect may be attributable to the
short half-life of these compounds. An alternative postulate is the potential
for compensatory mechanisms in the parasite life-cycle that may facilitate
excystation in an inhibitory environment. For example, it has been shown
that cysteine proteases can proteolytically degrade the AAT molecule and
effectively eliminate its inhibitory potential for serine proteases (Johnson et
al., 1986; Potempa et al., 1986; Wright and Scarsdale, 1995). The presumptive
indication of cysteine protease activity in CPH suggests a mechanism to
potentially mediate the inhibitory effects of AAT on oocyst excystation.
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In summary, the findings of this study suggest that multiple proteolytic
components, one sensitive to serine protease inhibitors and the other to the
cysteine protease inhibitor E-64, are expressed by C. parvum during
excystation. These findings further suggest that cryptosporidial serine
proteases are functionally associated with excystation. It is of particular
interest to note that PMSF, AAT, and aprotinin, in addition to inhibiting
excystation, have previously been shown to significantly reduce C. parvum
infection in a permissive BFTE cell culture system (Forney et al., 1996a; Yang
et al., 1996). Thus, protease inhibitors may reduce parasite infectivity in vitro
by antagonizing excystation. Altering the dynamics of excystation may
potentiate an effective anticryptosporidial strategy.
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Table 3-1. Effect of protease inhibitors on excystation of Cryptosporidium parvum oocysts.

.

% Inhibition

Protease Inhibitor

Concentration

1st

30

60

90

phenylmethylsulfonyl fluoride (PMSF)

10 mM

87.9f± 12.6

78.9f ± 9.1

56.1f± 5.8

11.3 ± 1.6

diisopropyl fluorophosphate (DIFP)

lOmM

66.7f ± 10.8

64.6+ ± 11.6

42.5+ ± 5.9

1.9 ± 1.5

aprotinin

100 11g/ml

48.5f± 12.7

50.9f± 8.3

25.2:t:± 4.7

4.7 ± 1.6

alpha-1-antitrypsin (AA T)

100 11g/ml

82.8f± 11.8

65.4:t:± 4.1

36.1+± 5.9

16.4 ± 1.5

10mM

14.9 ± 8.1

12.7 ± 6.4

7.9 ± 1.2

-1.6± 1.1

L-trans-epoxysuccinyl-leucylamindo(4-guanidino)-butane (E-64)

*Percent of control excystation inhibited by protease inhibitor treatment as described in Materials and
Methods. Data derived from duplicate samples from 3 separate experiments. Values represent mean ± SO.
+Time (min) of incubation at 37°C.
+Significantly different (P < 0.05) from control group.
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Table 3-2. Effect of selected inhibito rs on excystation-associa ted protease
activity.

Protease Inhibitor

PMSF

DIFP

Aprotinin

AAT

E-64

Concentration

10mM

88.4± 4.2t

1mM

67.0 ± 6.6t

10mM

80.8 ± 5.8t

1mM

72.6± 4.1t

100 ~g/ ml

65.7± 4.9t

10 ~g / ml

9.8 ± 2.6

100 ~g/ml

60.7± 4.4t

10 ~g / ml

30.8± 2.3:j:

10mM

37.7± 8.8t

1mM
PMSF + E-64

.

% Inhibition

10 mM (each)

22.6± 3.5:j:
95.8 ± 6.7t

*Percent of protease activity in CPH controls inhibited following treatment
with protease inhibitors as described in Materials and Methods. Data derived
from duplicate samples from 3 separate experiments. Values represent
mean± SD.
tsignificantly different (P < 0.01) from untreated control group.
+Significantly different (P < 0.05) from untreated control group.
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Figure 3-1. Effect of oocyst incubation time at 37°C on excystation and
protease activity. Percent excystation (primary Y-axis) observed at fixed
incubation intervals {-0-). A450 values (secondary Y-axis) for azocasein
hydrolysis in C. parvum homogenates (CPH) prepared from oocysts incubated
for designated intervals (--• --). Data points represent the mean value of
duplicate samples from a typical experiment; replicate experiments produced
similar results.
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CHAPTER4
ANTAGONISTIC EFFECT OF HUMAN ALPHA-1-ANTITRYPSIN ON
EXCYSTATION OF CRYPTOSPORIDIUM PARVUM OOCYSTS 1
ABSTRACT: This study evaluated the effects of the human serine

protease inhibitor alpha-1-antitrypsin (AAT) on in vitro excystation and
infectivity of Cryptosporidium parvum. Oocysts used in excystation studies
were subjected to bleach treatment, either directly from potassium
dichromate storage or following cesium chloride (CsCl) purification.
Unbleached CsCl-p.urified oocysts were used in control samples. Excystation
was monitored at 37°C in RPMI medium in the presence of 0, 100, 500, or 1000
Jlg / ml AAT. Samples were collected at timed intervals and the mean percent
of excystation in AAT-treatment groups was compared to untreated control
sample means. AAT significantly inhibited (P<0.05) excystation in a
concentration-dependent manner at incubation intervals from 15-90 min.
AAT did not significantly alter the excystation dynamics of unbleached
oocysts. The effects of AAT were further evaluated in cultured bovine
fallopian tube epithelial (BFTE) cells. Bleached oocysts, suspended in RPMI
medium containing 0, 1, 10, 100, 500, or 1000 Jlg / ml AAT, were used to
inoculate confluent BFTE cell monolayers. Inoculated cells were maintained
at 37°C until collected at 24, 48, 72, or 96 hr post-inoculation. Alternately,

'Coauthored by J. R. Forney, J. R. , S. Yang, and M. C. Healey. 1997. Journal of Parasitology 83:
(in press).
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sporozoites, excysted at 37°C and collected by filtration, were used to inoculate
BFTE cells under the same conditions. The mean number of parasites
counted in AAT-treated, oocyst-inoculated cells was significantly less (P<0.01)
than control mean values at 24 and 48 hr post-inoculation; longer postinoculation intervals (72-96 hr) exhibited a decreased inhibitory effect. AA T
did not significantly inhibit parasite infection when cultures were inoculated
with C. parvum sporozoites. These data suggest that the anticryptosporidial
potential of AAT is primarily associated with an antagonistic effect on oocyst
excystation.

INTRODUCTION

Cryptosporidium parvum (Apicomplexa: Cryptosporidiidae) is an
enteropathogenic parasite that causes a diarrheal illness in humans. This
protozoan preferentially invades the apical surface of epithelial cells lining
the small intestine and exhibits the potential to colonize the intestinal and
respiratory epithelia of immunocompromised hosts (Current et a!., 1983;
O'Donoghue, 1995). The severity of human cryptosporidiosis is appreciable in
the AIDS patient population and infection is frequently accompanied by
chronic, protracted diarrhea (Petersen, 1992; Goodgame eta!., 1993, 1995). A
number of potential anticryptosporidial compounds have been evaluated, yet
there remains no definitive treatment for cryptosporidiosis that eradicates the
parasite or reduces the chronicity of infection in susceptible hosts.
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Alpha-1-antitrypsin (AAT) is a single chain glycoprotein composed of
394 amino acid residues with a molecular weight of approximately 56 kDa
(Travis and Salvesen, 1983). AAT is found in peripheral circulation and
provides homeostatic regulation of proteolytic activity from endogenous
proteases (Baumstark, 1967; Perlmutter, 1993). In humans, AAT helps
mediate the systemic effects of inflammation and is particularly effective in
inhibiting its cognate target enzyme, neutrophil elastase. At present,
pharmaceutical preparations of AAT are therapeutically indicated to
supplement inadequate AAT levels in patients with congenital deficiencies;
its use as a potential anticoccidian reflects a novel application of the
compound.
Previous investigators have proposed the induction of parasite-derived
mechanisms within the oocyst as the probable biochemical initiators of C.

parvum excystation (Fayer and Leek, 1984; Reduker and Speer, 1985; Reduker
et al., 1985; Woodmansee, 1987). Enzyme activity, specifically endogenous
proteolysis, has been shown to facilitate excystation in the protists Giardia

muris and Eimeria tenella (Feeley et al., 1991; North, 1992; McKerrow et al.,
1993; Michalski et al., 1994). Cryptosporidial oocyst can be induced to excyst by
incubating at elevated temperatures and, although the level of excystation is
quite low, water or buffered saline can serve as an excystation medium at 37°C
(Fayer and Leek, 1984; Current, 1990). Exposing oocysts to protocols that
putatively enhanced the permeability of the oocyst wall significantly increases
the rate of excystation at 37°C. Accordingly, bleach treatment, acidification,
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deoxycholic acid, taurocholic acid, and trypsin have been reported to optimize
excystation and subsequent in vitro infection (Reduker et a!., 1985; Robertson
eta!., 1993; Upton eta!., 1994).
Although a role for proteolytic activity in excystation has been
postulated for several years, only recently has proteolytic enzyme activity
been reported in C. parvum. Okhuysen et a!. (1994) reported arginyl
aminopeptidase activity in excysted C. parvum sporozoites and suggested a
putative role for aminopeptidase activity in excystation. A subsequent report
by Nesterenko et a!. (1995) demonstrated cysteine protease activity in
solubilized membrane fractions of excysted sporozoites. Our previous studies
have detected proteolytic activity (azocasein hydrolysis) in a parasite
homogenate prepared from oocysts and sporozoites during peak periods of
excystation (Forney eta!., 1996a). Further, we have reported an interaction
between AAT and C. parvum that suggests the formation of serpin:enzyme
complexes immunolocalized on the surface of freshly excysted sporozoites
(Forney eta!., 1996b).
In the present study we have pursued a thorough evaluation of the

antagonistic effect of human AAT on the excystation of C. parvum oocysts. In
particular, experiments were designed to investigate oocyst wall permeability,
enhanced by bleach treatment, as a factor in AAT-mediated inhibition of
excystation. We further evaluated the anticryptosporidial activity of AAT on
both oocyst- and sporozoite-inoculated cultures and monitored serpin effects
on in vitro infectivity over extended post-inoculation incubation intervals.
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MATERIALS AND METHODS

Parasite isolation and preparation

Oocysts (Iowa strain) used in this study were propagated in
experimentally infected Holstein calves, isolated from feces using sucrose and
isopycnic Percoll gradients (Arrowood and Sterling, 1987), and stored in
potassium dichromate (K2 Cr 20 7) at 4°C. In preparation for analysis, oocysts
were packed by centrifugation and the bulk of the K2Cr20 7 was removed. The
oocyst pellet was decontaminated in a 20% bleach (v / v) solution (Chlorox®,
5.25 %sodium hypochlorite in stock concentration) for 10 min at 4°C and
washed thoroughly with sterile Hanks' balanced buffered saline (HBSS,
HyClone Laboratories, Logan, Utah) to remove residual bleach and K,Cr20 7 •
Oocysts were harvested by centrifugation and resuspended in sterile RPMI
medium (HyClone). Alternately, the oocyst pellet was purified by CsCl
flotation (ref) and used either directly following CsCl-purification or treated
with bleach as previously described. CsCl-purified oocysts were washed in
HBSS and resuspended in RPMI medium.
Bleached-decontaminated oocysts, prepared directly from K,Cr20 7
storage, were used in BFTE cell infectivity studies. Sporozoites for cell culture
inoculation were prepared from bleach-decontaminated oocysts suspended in
RPMI medium at a concentration of 1 X 107 oocysts/ml. The oocyst
suspension was aspirated into sterile, prewarmed syringes, and incubated at

37•c for 1 hr. The resulting mixture of oocysts and sporozoites was passed
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through a sterile 5-J,J.m filter (Millipore Corporation, Bedford, Massachusetts)
under gentle pressure and resuspended in RPMI medium to a final
concentration of 2 X 106 / ml sporozoites. Samples of the filtered sporozoite
inoculum were examined by brightfield microscopy and found to be negative
for intact oocysts.

Excystation studies
AAT (Chemicon International, Temecula, California) was initially
reconstituted as a 2000-J,J.g / ml stock solution in sterile RPMI medium and
further diluted in lli'MI medium as needed. Oocyst samples (i.e., bleachtreated before or after CsCl-purification) were mixed with AAT at
concentrations of 100, 500, and 1000 J,J.g/ ml. Intact oocysts were counted in
each sample using a hemocytometer and phase contrast microscopy to
establish a baseline oocyst number prior to incubation. Oocysts were then
incubated at 37°C, removed from the incubator at fixed time intervals (15, 30,
60, 90, 120, and 180 min), placed on ice to suppress further excystation, and
intact oocysts were again counted. Unbleached, CsCl-purified oocysts were
evaluated as control samples, both with and without AAT in the excystation
medium. Because of the low rate of excystation observed for unbleached
oocysts, incubation intervals were extended to 1-hr increments for a total of 6
hr when assessing AAT effects. Empty "ghost" oocysts and partially excysted
oocysts were not included in the enumeration process. The difference in the
number of oocysts counted before and after incubation was expressed as a
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percent of the original, pre-incubation number. This value was termed the
"percent of excystation" and used for comparative analysis of excystation
between treated and control samples.

In vitro infectivity
Infectivity studies involved the inoculation of BFTE cells with 105
bleach-decontaminated oocysts/ml in RPMI medium containing AAT at
concentrations of 1, 10, 100, 500, and 1000
was passed through a

0.8-~m / 0.2-~m

~g / ml.

The stock serpin solution

syringe filter (Acrodisc® PF, Gelman

Sciences, Ann Arbor, Michigan) prior to use in cell culture and further
diluted in RPM! medium as required. A 1.0-ml aliquot of the inhibitor:oocyst
mixture was used to inoculate BFTE cell monolayers grown to confluence on
glass coverslips placed in individual wells of a 24-well culture plate (Coming
Glass Works, Corning, New York). Monolayers inoculated with C. parvum
oocysts in the absence of serpin treatment served as an infection control
group. Inoculated cells were maintained in a candlejar at 37°C for 24 hr
(Luechtfeld et a!., 1982). After 24 hr incubation, the residual inoculum was
rinsed off with sterile RPMI medium and cell monolayers were retreated with
RPM! medium containing the same concentration of AAT as in the
inoculum; coverslips representing the 24-hr post-inoculation treatment
group were collected at this time. The remaining treatment groups were
further incubated at 37°C / 5% C02 and collected at 48-, 72-, and 96-hr postinoculation. A second experiment involved the addition of AAT to BFTE cell
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monolayers that had been inoculated with 105 C. parvum oocysts and
cultured for 24 hr prior to treatment. Coverslips were collected 24 hr after
AAT treatment was applied to the established infections. A third treatment
protocol involved the use of C. parvum sporozoites as a source of culture
inoculum. Sporozoites were mixed with the same AAT levels noted
previously to achieve a final concentration of sporozoites at 1 X 106 /mi. A
1.0-ml aliquot of the AAT:sporozoite mixture was applied to BFTE cell
monolayers and inoculated cells were maintained as described. Coverslips
were collected at 24 and 48 hr post-inoculation. A final investigation
paralleled the initial experiment, but was limited to a single AAT
concentration (1000 f,!g/ml) in an oocyst inoculum. Treatment included the
reapplication of AAT each 24-hr interval following the initial inoculation to
evaluate the effect of daily retreatment; this manipulation helped ensure
sufficient bioavailability of the serpin compound. Coverslips were collected
at 24, 48, 72, and 96 hr post-inoculation. In all experiments, cell monolayers
were removed at designated intervals, washed with RPMI medium, fixed in
absolute methanol (10 min/25°C), rinsed with 25 mM PBS, and stained with
Giemsa. Coverslips were mounted (inverted) on glass slides with a
permanent mounting medium and examined by brightfield microscopy.
Parasite enumeration

Parasite enumeration in infected BFTE cells was performed by the
method of Yang et al. (1996). In brief, parasites were counted in a single scan
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(1,000X, oil immersion) across the diameter of a mounted coverslip (approx.
65 high power fields). Intact oocysts observed in BFTE cell monolayers at the
end of the designated post-inoculation periods were considered to be residual
inoculum and were not counted. The mean number of parasites counted in
each of the AAT treatment groups was expressed as a percent of the mean
number of parasites counted in the infection control group. Differences in
infection numbers were compared for statistical significance by simple
ANOVA (Fisher's PLSD).

RESULTS

Excystation

The observed excystation dynamic of bleach-treated oocysts was
consistent with previous reports (Fayer and Leek, 1984; Woodmansee, 1987;
Upton et al., 1994). The percent of excystation increased rapidly during the
initial 90 min of incubation at 37°C with a progressive decline in the rate of
excystation after 180 min incubation (Fig. 4-1). Unbleached CsCl-purified
oocysts excysted at low levels over extended incubation periods. These
oocysts required 37°C incubation for 6 hr before reaching mean excystation
levels of

~30%;

comparable excystation yields were obtained within 30 min

with bleach-treated samples.
AAT significantly inhibited (P<O.OS) excystation of bleach-treated
oocysts in a concentration dependent manner (Fig. 4-2). The observed
antagonistic effect was particularly evident during the early incubation
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intervals from 15-90 min, but decreased progressively with extended
incubation times. Further, both the duration of excystation inhibition and
the degree of recovery were influenced by serpin concentration. Variation in
bleach treatment (i.e., bleached directly from K2Cr,0 7 storage or following
CsCI-purification) had no significant effect on AAT-mediated inhibition. As
shown in Figure 4-3, excystation of CsCI-purified oocysts was not significantly
inhibited by 1000 11g/ ml AAT; similar results were obtained for lower
concentrations of the serpin (data not shown).
In vitro infectivity
AAT, at concentrations <!10 llg / ml, significantly inhibited (P<0.01)
parasite infection in the 24- and 48-hr post-inoculation groups in cells
inoculated with bleach-treated oocysts (Table 4-1). The inhibitory effect of
AAT exposure decreased with increased culture incubation intervals;
significant inhibitory activity (P<0.01) was limited to serpin levels <!500 11g/ ml
in the 72-hr post-inoculation group and <! 1000 11g/ ml at 96 hr after
inoculation. BFTE cell monolayers with established C. parvum infection
were refractory to AAT and no significant inhibition was observed at any of
the time periods evaluated (Table 4-1).
AAT had no significant inhibitory effect on parasite numbers when
sporozoites were used to inoculate BFTE cell cultures (Fig. 4-4). Similarly, the
reapplication of human serpin at 24-hr intervals for the duration of postinoculation incubation periods did not significantly enhance the inhibitory
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effect of the compound on in vitro infection relative to a single reapplication
of AAT (Fig. 4-5).
The observed results led us to question whether AAT had an adverse
effect on BFTE cells such that parasite numbers were reduced independent of
any potential anticoccicial activity. To help clarify this issue, BFTE cell
monolayers were incubated with each of the respective concentrations of
AAT for 24 hr prior to inoculation. Cells were then rinsed 4 times with RPMI
medium to remove residual serpin, inoculated with either bleach-treated
oocysts or sporozoites, and reincubated at 37°C/5% CO, for 24 hr. Infection
rates obtained following AAT preincubation were not statistically different
from the mean number of parasites counted in control samples preincubated
with RPMI medium in lieu of AAT (data not shown). No cytotoxic effects
were observed in culture cells incubated for up to 96 hr with AAT at the
concentrations noted.
DISCUSSION
The results of the present study provide substantial evidence to link
the in vitro anticryptosporidial activity of AA T to an antagonistic effect on
oocyst excystation. This association is apparent from the differential
inhibitory capacity of AAT on oocyst-inoculated cell cultures and the absence
of significant inhibition on established in vitro infections. The lack of
anticryptosporidial efficacy in this later group suggests that AAT exerts
minimal effect on the asexual propagation of intermediate stages (merogony).
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Further, AAT did not demonstrate a significant inhibitory effect on BFTE cells
inoculated with freshly excysted sporozoites, suggesting that serpin activity
does not alter parasite attachment and invasion. Neither was the diminution
of anticryptosporidial activity over extended post-inoculation intervals
attributable to a lack of biological availability of the serpin compound;
retreatment of infected BFTE cells at daily (24-hr) intervals did not preclude
the loss of inhibitory efficacy.
Our data indicated that while AAT reduced the rate of excystation for
bleached-treated oocysts, the serpin did not inhibit the excystation of
unbleached oocysts. These findings suggest that parasite excystation is
dependent upon endogenous mechanisms that are protected from serpin
activity by the oocy5t wall. It is further apparent that permeability of the
oocyst wall is requisite for AAT interactions with oocysts and/or sporozoites
sufficient to alter excystation prior to the emergence of viable sporozoites.
The oocyst wall is an effective barrier to AAT as long as the integrity of the
wall remains intact.
Infection control samples (i.e., lacking AAT treatment) inoculated with
sporozoites had considerably lower infection rates and exhibited greater
variability than observed in cells inoculated with oocysts. While microscopic
examination of aliquots taken from sporozoite suspensions prior to
inoculation did not reveal the presence of intact oocysts, oocysts were
occasionally encountered on sporozoite-inoculated coverslips. Filtration
methods to produce C. parvum sporozoites minimize handling and reduce
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the time interval from excystation to culture inoculation, but do not
completely eliminate the inadvertent inclusion of oocysts in the final
inoculation. Some of the variation noted in AAT treatment of sporozoiteinoculated cells may be influenced by serpin effects on spurious oocysts in
filtered samples and may not be solely representative of AAT effects on the
early stages of in vitro infection. These groups lacked the concentration- and
time-dependent relationships between AAT treatment and parasite numbers
observed in oocyst-inoculated cultures.
The antagonistic effect of AA T on excystation appears to be a transient
process; continued incubation produced excystation yields levels approaching
approximately 65-90% of the control group mean values. Despite the relative
increase in excystation with continued incubation, it is noteworthy that oocyst
inoculum containing AAT had significantly lower infection levels in the
early post-inoculation treatment groups. The viability of emerging
sporozoites appears to be directly related to the time lapse between the
induction of excystation-related activity and final escape from the oocyst wall.
Specifically, the time lag between the initial activation of excystation and the
availability of susceptible host cells is a critical factor in C. parvum infectivity.
The viability of excysted sporozoites is significantly diminished by excessive
handling or delays in inoculating cultures (Robertson et a!., 1993). Sporozoite
viability is relatively intolerant of delayed emergence and a loss of infectivity
is evident in AAT-treated oocysts. It is reasonable to speculate that a
significant portion of the finite energy stores within the sporozoite may be
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consumed in the excystation process; failure to find an obligatory host cell
shortly after emergence is detrimental to parasite infectivity. A similar
relationship between sporozoi te energy expenditure and diminished viability
has been reported in the related coccidian Eimeria tene/la (Yashwant et a!.,
1993).

The findings presented support previous asertions that parasitederived biochemical mechanisms induced by elevated temperature and,
possibly, other conditions in the microenvironment of excysting oocysts
trigger the activation and emergence of sporozoites (Fayer and Leek, 1984;
Woodmansee, 1987). Of particular interest is the association between
antagonized excystation during initial incubation intervals and a subsequent
reduction in BFTE cell infection demonstrated in this study. The
implications of these findings suggest that not only is excystation induced by
an activation of enzymatic processes, but once activated, bioenergetic demand
may be the most important limitation of sporozoite viability.

On the basis of this study, we conclude that AAT antagonizes C.
parvum excystation when it can gain entry into the oocyst; enhanced
permeability of the oocyst wall is necessary for the serpin to inhibit
excystation. Further, these data suggest that sporozoite activation within the
intact oocyst wall includes, at least in part, the expression of proteolytic
enzyme activity. It is the association of protease activity with excystation, and
the functional specificity of the AAT molecule for the active site of serine
proteases, that provides the most likely mechanism for serpin-mediated
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inhibition. The delayed excystation dynamic attributed to AAT accounts for
its anticryptosporidial activity against in vitro infection, putatively by altering
endogenous proteolytic activity within the intra-oocyst milieu.
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Table 4-1. In vitro anticryptosporidial activity of alpha-1-antitrypsin in BFTE cell culture.

% Infection Control

[AAT]'

+24t

24

48

72

96

0

100

100

100

100

100

1

99.8± 8.91

66.4± 9.2ll

72.6± 7.32+

87.4± 12.24

96.9 ± 11 .82

10

97.5 ± 9.91

48.0± 4.24+

56.1 ± 4.54+

82.1 ± 11.15

96.2± 9.68

100

95.2 ± 10.11

38.4± 6.47+

44.4±14.41+

74.9 ± 10.04

81.1 ± 12.17

500

88.2± 12.37

17.2 ± 12.93+

27.3± 9.68+

46.3± 8.62+

62.6 ± 11.21

1000

82.5 ± 18.81

10.8 ± 5.76+

18.7± 5.97+

31.6± 9.15+

43.1 ± 7.12+

• Concentration in Jlg / ml.
touration of AAT exposure (hr). A positive(+) sign indicates treatment was delayed until
after inoculation; all other groups were treated at the time of culture inoculation with C.
parvum oocysts.
+Significantly different from control group (.!:<0.01); data represent mean± SD for duplicate
samples in 2 separate experiments.
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Figure 4-1. Pattern of excystation fo r bleach-treated Cryptosporidium parvum
oocysts. Excystation yield from oocysts harvested directly from K,Cr20 7
storage (-o-) or following CsCl-purification (-e-) compared to unbleached
CsCl-purified oocysts (-• -). Values represent mean± SO for 3 replicates from
each of 3 separate experiments.
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Figure 4-2. Antagonistic effect of alpha-1-antitrypsin on Cryptosporidium

parvum excystation. CsCI-purified, bleach-treated oocysts incubated at 37°C in
the presence of 100 (-•-), 500 (-e-), or 1000 (-o-) J.Lg / ml purified human
AAT. Data for bleach decontaminated oocysts from K,Cr 20 7 storage was
similar. Values represents mean± SO for duplicate samples from 3 separate
experiments.

110

100
80

--"'
r:::

.:=
nl

60

>,
u

><

~

40

0~

20
0
1

2

3

4

5

6

Incubation time (hr)

Figure 4-3. Effect of alpha-1-antitrypsin on excystation of unbleached

Cryptosporidium parvum oocysts. CsCl-purified oocysts incubated at 37°C in
RPMI containing 1000 !lg/ ml human AAT (-o-) relative to untreated control
samples (-e-). Values represents mean percent excystation for each
incubation interval

± SO for duplicate samples from 2 separate experiments.
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Figure 4-4. Effect of alpha-1-antitrypsin on infection of cultured epithelial
cells inoculated with Cryptosporidium parvum sporozoites. Filter-isolated
sporozoites were cultured in RPM! medium containing AAT for 24-hr (-e -)
or 48-hr (-o-) post-inoculation intervals. Values represents mean ± SO for
duplicate samples from 2 separate experiments.
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Figure 4-5. Effect of alpha-1-antitrypsin retreatment on parasite numbers in
cultured epithelial cells inoculated with Cryptosporidium parvum oocysts.
Data represents the mean number of parasites counted in BFTE cell
monolayers, expressed as a percent of untreated control sample means,
containing 1000

~-tg/ml

AAT and cultured for 24 (white bar) or 48 (black bar)

hr post-inoculation. Values indicate mean± SO for duplicate samples from 2
separate experiments.
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CHAPTERS
IN VITRO ANTICRYPTOSPORIDIAL POTENTIAL OF SERINE
PROTEASE INHIBITORS

INTRODUCTION

This chapter comprises 3 separate manuscripts originally prepared in
the abbreviated format of a Research Note consistent with the requirements
of the publishing journal. Though prepared as individual manuscripts, these
notes provide a composite evaluation of the anticryptosporidial potential of
select protease inhibitors with a particular emphasis on AAT. The ultimate
contribution of this dissertation may reside in the applicability of these
studies to the needs of the medical community; the increasing incidence of
cryptosporidiosis in immunodeficient and immunocompromised
individuals has substantially increased the morbidity and mortality of HIV
infection. Overwhelming bouts of diarrheal illness, in excess of 70 liters of
watery diarrhea a day, severely degrade the quality of life for AIDS patients.
The lack of a curative agent to combat chronic cryptosporidial infection is a
very real problem and efforts to identify candidate compounds for therapeutic
trial are a worthy endeavor.
The reader should recognize the progressive evolution and refinement
of the studies upon which this chapter is based. The initial evaluation of
AA T as a potential anticryptosporidial compound revealed a potent effect for
the inhibitor in concentrations 2': 100 !lg/ml. Subsequent studies showed that
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the inhibitory potential of AAT was noted at much lower levels and peaked

at 24- to 48-hr post-inoculation; we later noted that efficacy waned when postinoculation intervals were extended to 2': 72 hr. It became increasingly
apparent that AAT, and possibly other compounds in the general class of
serine protease inhibitors, were potent antagonists of excystation of C.

parvum oocysts. As an antiexcystation agent, it is reasonable to suggest that
the reduction in initial excystation rates observed in the presence of AAT
contributed to the decreased infectivity pattern noted in cell cultures
inoculated with C. parvum oocysts.
The amplification cycle of type I meronts appears to be refractory to
serpin activity and the observed loss of in vitro efficacy for AAT during
mergony likely reflects the propagation of intermediate stages of C. parvum.
This hypothesis is strongly supported by results indicating a decreased
inhibitory potential for AAT during prolonged post-inoculation intervals and
a lack of significant inhibition of established infections. Further, AAT had no
significant inhibitory effect on infection when excystation was accomplished
prior to inoculation; sporozoite inocula containing AAT produced in vitro
infection rates statistically indistinguishable from untreated control groups.
The potent inhibition of excystation and early infection by AAT,
followed by a progressive loss of anticryptosporidial activity, led to the
consideration of a multi-compound evaluation. A strategy was employed to
exploit the anticryptosporidial characteristics of AAT in combination with a
second anticryptosporidial agent that preferentially targeted developmental
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intermediates of the parasite. The aminoglycoside paromomycin was selected

as a second treatment compound and this combination (i.e., AAT and
paromomycin) demonstrated a potent synergistic activity against C. parvum
infection in vitro. Thus, a rational approach to multi-compound evaluation
in an in vitro system proved to be a highly successful strategy in preventing
cryptosporidial infection.
The manuscripts presented in this chapter have been modified from
their original style to conform to format consistency and facilitate the reader's
review of their contents. The abstract prefacing each section has been
summarized in this introduction and a single, comprehensive literature cited
section completes the chapter.
EFFICACY OF SERINE PROTEASE INHIBITORS AGAINST

CRYPTOSPORIDIUM PARVUM'

The dynamic of host cell infection by Cryptosporidium parvum
(Apicomplexa: Cryptosporidiidae) and the parasite's enigmatic residence
within an intramembranous vacuole are poorly characterized events in the
life-cycle of this organism. Other apicomplexan species reportedly undergo a
series of events during which the apical complex of the organism attaches,
orients, and, ultimately, facilitates penetration of the host cell membrane to

1

Coauthored by J. R. Forney, J. R., 5. Yang, C. Du, and M. C. Healey. 1996. Journal of
Parasitology 82: 638-640.
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assess an intracellular location for growth and development (Aikawa et a!.,

1978). The biochemical properties of sporozoans appear to include 1 or more
protease-mediated steps in the host cell adhesion and invasion process.
Hadley et a!. (1983) demonstrated a protease-dependent mechanism involved
in parasite attachment and penetration of erythrocytes by Plasmodium

knowlesi merozoites. Their study reported a significant reduction in
infectivity following the exposure of merozoites to selected protease
inhibitors. Other investigators have reported analogous findings in

Plasmodium falciparum (Dluzewski et a!., 1986), Eimeria tene/la (Fuller and
McDougald, 1990), and Eimeria vermiformis (Adams and Bushell, 1988), in
which protease inhibitors reduced the in vitro infection of permissive host
cells.
The present study evaluated the anticryptosporidial potential of the
protease inhibitors alpha-1-antitrypsin (AAT), antipain, aprotinin, leupeptin,
methoxysuccinyl-ala-ala-pro-valine chloromethylketone (MAAPVCK),
soybean trypsin inhibitor (SBTI), and phenylmethylsulfonyl fluoride (PMSF)
in a bovine fallopian tube epithelial (BFTE) cell culture system. Our previous
study (Forney eta!., 1996b) detected a functional interaction between human
AAT and C. parvum, primarily associated with the invasive form
(sporozoite) of the parasite. The functional specificity of AAT for the active
site of serine proteases influenced the selection of inhibitors used in the
present study. Our objective here was to evaluate the efficacy of the selected
protease inhibitors in reducing the in vitro infectivity of C. parvum.
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The BFTE cell culture system used in this study supports the complete

development, i.e., asexual and sexual reproductive cycles, of C. parvum (Yang
et a!., 1996) and has been validated as an analytical tool for screening potential
anticryptosporidial compounds in previous studies with Immuno-C™
(Healey eta!., 1996) and paromomycin (S. Yang, per. comm.). Protease
inhibitors AAT (Chemicon International, Inc., Temecula, California),
antipain (ICN Biochemicals, Inc., Aurora, Ohio), aprotinin (ICN), leupeptin
(Calbiochem-Novabiochem Corp ., La Jolle, California), and SBTI
(Calbiochem) were initially prepared in stock solutions of 10, 20, 100, 200, and
1000 J.Lg/ml in RPM! medium (Hyclone Laboratories, Logan, Utah).
MAAPVCK (Sigma Chemical Co., St. Louis, Missouri) and PMSF (Sigma)
were first dissolved in dimethyl sulfoxide (DMSO; Sigma) and subsequently
diluted in RPM! medium to prepare the same concentrations (MAAPVCK) or
2, 4, and 6 mM concentrations (PMSF). Oocysts used in this study were
successively propagated in Holstein calves. Isolated oocysts (Arrowood and
Sterling, 1987) were decontaminated in 10% bleach for 20 min at 4°C, washed
thoroughly with sterile Hanks' balanced buffered saline (HBSS), and
resuspended in sterile RPM! medium. Immediately prior to inoculation,
purified C. parvum oocysts were added to the previously prepared protease
inhibitor dilutions to obtain 105 oocysts / ml at the final inhibitor
concentrations tested, i.e., 5, 10, 50, 100, and 500 J.Lg / ml or 1, 2, and 3 mM for
PMSF. A 1.0-ml aliquot of the inhibitor:oocyst mixture was used to inoculate
BFTE cell monolayers grown to confluence on glass coverslips placed in
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individual wells of a 24-well culture plate. Each protease inhibitor
concentration was tested in either 2 (antipain, leupeptin, SBTI, PMSF,
MAAPVCK) or 4 (AAT, aprotinin) well replicates in duplicate experiments.
At least 2 wells per plate were inoculated with C. parvum oocysts in the
absence of inhibitor treatment and served as an infection control group.
Inoculated cells were maintained in a candlejar environment at 37°C.
Coverslips were removed at 24 hr postinoculation and washed with sterile
RPM! medium. Cell monolayers were fixed 10 min in 100% methanol, rinsed
twice with 0.025 M PBS, stained with Giemsa for 2 hr, and rinsed with
distilled water. Coverslips were mounted (inverted) on glass slides with a
permanent mounting medium and examined by brightfield microscopy (oil
immersion, lOOOX).
Parasite enumeration was accomplished as previously described (Yang
et al., 1996). Oocysts observed in the BFTE cell monolayers at the end of the
incubation period were considered to be residual inoculum and not included
in the enumeration process. The mean number of parasites counted in each
of the protease inhibitor treatment groups was expressed as a percentage of
the mean number of parasites counted in the infection control group. The
difference between mean values for treatment and control groups was
compared for statistical significance by ANOVA (Fisher's PLSD) using a
StatView® statistical analysis application.
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BFTE cells were permissive to C. parvum infection. Typically, at 24 hr

post-inoculation, the infection control group exhibited a predominance of the
type I and II meront developmental stages with few, if any, residual oocysts
remaining from the inoculum. Parasite numbers were significantly reduced
(P < 0.01) following treatment with leupeptin and SBTI at concentrations of 10
and 50

~-tg / ml,

respectively (Table 5-1). The protease inhibitors AAT, antipain,

and aprotinin significantly reduced (P < 0.001) parasite numbers at
concentrations as low as 5-10

~-tg / ml.

MAAPVCK did not significantly reduce

C. parvum infection of BFTE cells at any of the concentrations tested. PMSF

significantly reduced (P < 0.001) parasite numbers to 40% of control values at a
concentration of 3 mM (Table 5-2) .
AA T, antipain, and aprotinin were the most potent inhibitors of C.
parvum infection in the BFTE cell culture system. When concentrations of

these protease inhibitors were increased to 1,000

~-tg / ml

in the inoculum,

parasite numbers were reduced to 1.76 ± 0.4% (AAT), 6.64 ± 1.44% (antipain),
and 9.44 ± 1.81% (aprotinin) of the infection control mean (Fig. 5-1). During
the microscopic enumeration of parasites in BFTE cell monolayers treated
with these 3 protease inhibitors, intact (unexcysted) oocysts were frequently
observed. This observation was predominantly associated with protease
inhibitor concentrations exceeding 100

~-tg/ml

and was confined to these 3

inhibitors. There was no evidence of cytotoxicity for BFTE cells at the
protease inhibitor concentrations evaluated in this study.

120
Anticryptosporidial potential attributable to protease inhibition
strongly suggests that the dynamic influencing initial host cell:parasite
interaction is facilitated by parasite protease activity. The present study
demonstrated a significant in vitro inhibition of C. parvum infection by AAT,
antipain, and aprotinin and significant, but quantitatively less, inhibition by
leupeptin, SBTI, and PMSF. These findings are generally consistent with
studies on related coccidians (Hadley eta!., 1983; Adams and Bushell, 1988;
Fuller and McDougald, 1990). PMSF was the most potent inhibitor of Eimeria
spp when evaluated at a concentration of 5 mM. Conversely, Hadley et a!.
(1983) reported no significant inhibitory effect by either PMSF or antipain on
erythrocyte invasion by P. knowlesi merozoites. In the present study, a lack of
significant inhibition by MAAPVCK, in light of the effects of AAT, antipain,
and aprotinin, is a presumptive indication that protease-like activity
expressed by C. parvum may more closely resemble a trypsin-like serine
protease, in terms of inhibitor sensitivity, rather than an elastolytic enzyme
(Stein and Trainor, 1986; Potempa eta!., 1994).
The results of this study add to the growing body of literature
addressing the essential metabolic and physiologic roles of proteases in
parasitic infection (North, 1992; Roose and Van Noorden, 1995). Parasite
protease activity has been associated with host cell attachment (Arroyo and
Aldrete, 1989), degradation of host proteins for parasite nutrition (Chappell
and Dresden, 1986), tissue migration and penetration (McKerrow eta!., 1990),
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cytotoxic effects (Lushbaugh et al., 1981), and parasite maturation and
development (Richer et al., 1993).
This study is the first to report a significant reduction in C. parvum
infection of cultured cells in the presence of protease inhibitors. These
findings support a hypothesis that protease activity, putatively a serine
protease enzyme, is an important biochemical constituent of the early
infection dynamics of C. parvum. A recent report of arginyl aminopeptidase
activity associated with C. parvum (Okhuysen et al., 1994) assessed a potential
role for aminopeptidase activity in the excystation of oocysts. Our
observation of intact residual oocysts in cell monolayers treated with serine
protease inhibitors strengthens the association between proteolytic activity
and excystation. These findings further suggest that the anticryptosporidial
potential of protease inhibitors may reduce host cell vulnerability to parasite
protease activity and may be a prefatory indication of a chemotherapeutic
strategy to abrogate cryptosporidial infection.
ANTICRYPTOSPORIDIAL POTENTIAL OF ALPHA-IANTITRYPSIN'

Cryptosporidium parvum is an intracellular protozoan parasite that
preferentially infects epithelial cells lining the microvilli of the small
intestine. Human cryptosporidiosis is particularly severe in the
'Coauthored by J. R. Forney, 5. Yang, and M. C. Healey. 1996. Journal of Eukaryotic
Microbiology 43: 635.
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immunocompromised hos t and is recognized as a significant cause of
morbidity in the AIDS patient population. The present lack of efficacious
therapy is an impetus for investigative efforts to identify potential
anticryptosporidial agents. Alpha-1-antitrypsin (AAT) is the major serine
protease inhibitor (serpin) in human circulation and has a substantial
homeostatic role in regulating excess proteolytic activity. Previous studies
have detected an interaction between human AAT and components of C.

parvum sporozoites (Forney et a!., 1996b). To evaluate the functional
significance of serpin interactions, we investigated the anticryptosporidial
potential of purified human AAT on 2 aspects of the early infection dynamics
C. parvum. In this present study, we report the effects of AAT on in vitro

excystation and cryptosporidial infection in a bovine fallopian tube epithelial
(BFTE) cell culture system.
Oocysts (Iowa strain) were amplified in Holstein calves. Isolated
oocysts (Arrowood and Sterling, 1987) were decontaminated in 10% bleach for
10 min at 4°C, washed with sterile HBSS, and resuspended in sterile RPM!
medium (HyClone Laboratories). Purified human AAT (Chemicon
International, Inc.) was initially prepared in stock solutions of 20, 200, 1000,
and 2000 Jlg/ml in RPM! medium. For excystation studies, oocysts were
mixed with equal volumes of the appropriate AA T stock solutions to obtain
final serpin concentrations of 10, 100, and 500 Jlg / ml. Intact oocysts were
counted in a hemacytometer using phase contrast microscopy. Oocysts were
then incubated at 37°C in the absence of any further treatment (Robertson et
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a!., 1993; Upton eta!., 1994). Tubes were removed from the incubation
environment at fixed time intervals, i.e., 15, 30, 60, 90, 120, and 180 min, and
intact oocysts were again enumerated (excluding empty oocyst "ghosts" and
partially excysted oocysts). The difference between the number of oocysts
counted prior to incubation and the number of oocysts counted after
incubation was expressed as a percent of the original (preincubation) number.
This value was termed "percent excystation" and represented an indirect
assessment of excystation. To evaluate serpin effects on infectivity, C.
parvum oocysts were added to the previously prepared AAT stock solutions

to obtain 105 oocysts / ml at inhibitor concentrations of 10, 100, 500, and 1000
f.!.g/ml. A 1.0-ml aliquot of each AAT:oocyst mixture was used to inoculate
separate BFTE cell monolayers grown to confluence on glass coverslips placed
in individual wells of a 24-well culture plate. Inoculated cells were
maintained in a candlejar environment at 37°C. Monolayers were removed
at 24 hr post-inoculation, washed with RPMI medium, fixed with absolute
methanol, and stained with Giemsa. Coverslips were mounted (inverted) on
glass slides with a permanent mounting medium and examined by
brightfield microscopy (oil immersion, 1000X). Parasite enumeration was
accomplished as previously described (Yang eta!., 1996). Intact oocysts
remaining after 24 hr incubation were considered residual inoculum and not
included in the enumeration process. The mean number of parasites counted
in each of the protease inhibitor treatment groups was expressed as a
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percentage of the mean number of parasites counted in an infection control
group .
Excystation studies demonstrated that AAT significantly (P<0.05)
inhibited oocyst excystation in concentrations<! 10 11g/ml (Table 5-3). The
inhibitory effect was greatest in the early incubation intervals from 0-60 min.
Excystation yields typically attained 70-75% of untreated control samples
when incubation was continued to 180 min with all but the highest levels of
AAT evaluated (Table 5-3) . The functional specificity of AAT for the active
site of serine protease enzymes suggests that protease activity, putatively a
serine protease, facilitates oocyst excystation.
Infectivity of C. parvum oocysts in BFTE cells was significantly
inhibited (P<0.01) at each of the AAT concentrations evaluated (Table 5-4).
Inhibition of in vitro infection exceeded 50% at AAT levels as low as 10
11g/ ml and reached 95.4% at a concentration of 1000 llg/ml. The frequent
observation of intact (unexcysted) oocysts in BFTE monolayers inoculated
with oocysts in the presence of high concentrations of AAT further suggests
an association between serpin activity and impaired excystation.
These data describe a potent in vitro anticryptosporidial potential for
human AAT and, collectively, strengthen the association between early
excystation intervals and subsequent in vitro infection of host cells
(Robertson eta!., 1993; Upton eta!., 1994). The findings of this study add to
emerging evidence suggesting a requisite role for proteolytic enzyme activity
in the infectivity of C. parvum (Forney et a!., 1996c; Nesterenko et a!., 1995;
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Okhuysen et al., 1994) and, further, suggest the potential use of serine protease
inhibitors in a therapeutic strategy to combat cryptosporidiosis.

SYNERGISTIC ANTICRYPTOSPORIDIAL POTENTIAL OF THE
COMBINATION ALPHA-I-ANTITRYPSIN AND
PAROMOMYCIN'

Cryptosporidium parvum (Apicomplexa: Cryptosporidiidae) is an
enteropathogenic protozoan that invades the intestinal epithelium in a
number of mammalian species (O'Donoghue, 1995). Cryptosporidiosis is
particularly severe in the immunocompromised human host and infection is
frequen tly characterized by a profuse, watery (termed "cholera-like") diarrheal
illness. Growing concern about the potential for human infection,
particularly as acquired through municipal water supplies, and the sequela of
chronic infection in susceptible hosts constitutes a significant emerging
infectious disease threat (CDC, 1994; MacKenzie et al., 1994). The
formidability of chronic infection is accentuated by the present lack of
efficacious therapy. The search for anticryptosporidial agents has included the
evaluation of numerous compounds in various in vitro and in vivo models,
as well as in human clinical trials. This pursuit has been plagued by
inconsistent therapeutic responses, recrudescence of infection following

'Coauthored by J. R. Forney, S. Yang, and M. C. Healey. Antimicrobial Agents and
Chemotherapy (submitted March 1997).
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cessation of treatment, and the apparent autoinfective life-cycle of C. parvum
in chronic infection states.
Reports of proteolytic enzyme activity in the early developmental
stages of C. parvum have prompted consideration of serine protease, cysteine
protease, and arginyl aminopeptidase inhibitors for anticryptosporidial
properties. Okhuysen et al. (1994) first reported cryptosporidial
aminopeptidase activity and further demonstrated the ability of alphaaminoboronic acid derivatives to inhibit C. parvum peptidase activity and
oocyst excystation (Okhuysen et al., 1995). Other investigators have reported
cysteine protease activity associated with C. parvum sporozoite membrane
fractions (Nesterenko et al., 1995) and a reduction in parasite infectivity
following exposure of sporozoites to the cysteine protease inhibitor L-transepoxysuccinyl-leucylamindo-(4-guanidino)-butane (E-64) in MOCK cell
culture (Huang and Petersen, 1996). Additionally, we have demonstrated a
potent anticryptosporidial potential for select serine protease inhibitors,
including human alpha-1-antitrypsin (AAT), in a bovine fallopian tube
epithelial (BFTE) cell culture system (Forney et al., 1996b). These collective
observations strongly suggest that protease/peptidase activity is requisite for
the early infection dynamics of C. parvum and further suggest a potential
chemotherapeutic role for protease inhibitors in controlling cryptosporidiosis.
Marshall and Flanigan (1992) reported a significant reduction in C.

parvum infection in a differentiated human enterocyte cell line, HT29.74,
using the aminoglycoside paromomycin. Further studies have reported a
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significant anticryptosporidial effect for paromomycin in immunosuppressed
mice (Healey eta!., 1995), immunosuppressed rats (Rehg, 1994; Verdon eta!.,
1994), calves (Fayer and Ellis, 1993b), SCID mice (Tzipori eta!., 1994), and in
human clinical trials (Clezy eta!., 1991; Fichtenbaum eta!., 1993; Bissuel eta!.,
1994; Flanigan eta!., 1996). A report of paromomycin treatment followed by
the administration of letrazuril noted an improved therapeutic response in
treating AIDS-related cholangitis (Hamour eta!., 1993). Fayer and Ellis (1993a)
evaluated the anticryptosporidial efficacy of select aminoglycosides, to include
paromomycin, in single and combined therapy trials with tetracycline, in a
neonatal mouse model. Their findings showed a significant reduction in
cryptosporidial infection following administration of paromomycin, but did
not reveal a synergistic effect in combination with tetracycline derivatives.
In the present study we evaluated the combined effects of the serine

protease inhibitor (serpin) AAT and paromomycin in BFTE cell culture. A
putative role for serpin activity in antagonizing oocyst excystation (Forney et
a!., 1996a) and the anticryptosporidial efficacy of paromomycin, particularly
against intermediate stages of C. parvum, suggests that these compounds
target different stages in the developmental life-cycle of the parasite. Our
specific intent was to exploit the potential for enhanced efficacy from these 2
compounds when used simultaneously in an in vitro assay.
Oocysts used in this study were propagated in experimentally infected
Holstein calves, isolated from feces using discontinuous sucrose gradients
(Arrowood and Sterling, 1987), and stored in 2.5% potassium dichromate
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(K 2Cr 20 7) at 4°C. Prior to cell culture inoculation, oocysts were
decontaminated with a 10% (v /v) bleach solution for 10 min at 4°C and
washed with HBSS to remove residual K 2Cr 20 7 and bleach. Bleachdecontaminated oocysts were resuspended in RPMI.1640 base medium (RPMI;
HyClone Laboratories, Logan, Utah) at a concentration of 2 X 105 oocysts/ml.
Primary BFTE cell cultures were prepared by the method of Yang et al.
(1996) and used to evaluate anticryptosporidial activity. In brief, epithelial
cells were collected from the mucosal surface of bovine fallopian tubes (E. A.
Miller & Sons Packing Company, Hyrum, Utah) by flushing the tubes
multiple times with sterile HBSS. Cells were thoroughly washed in HBSS,
packed by centrifugation (200 X g for 10 min), introduced into culture flasks
containing RPMI supplemented with 10% fetal bovine serum (FBS; HyClone),
and cultured at 37°C/5% C02 . Cells were trypsinized and seeded onto glass
coverslips in individual wells of 24-well culture plates (Coming Glass Works,
Corning, New York) using unsupplemented RPMI. BFTE cells were
maintained at 37°C/5% C02 until monolayers reached confluence.
Stock solutions of human AA T (Chemicon International, Inc.,
Temucula, California) and paromomycin (Warner Lambert/Parke Davis,
Ann Arbor, Michigan) were prepared in RPMI at concentrations of 1000

IJ.g/ml (AAT) or 2400 IJ.g/ml (paromomycin) and passed through a 0.8IJ.m/0.2-j.lm syringe filter (Acrodisc® PF, Gelman Sciences, Ann Arbor,
Michigan). Stock concentrations were further diluted in RPMI as needed.
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To evaluate the differential efficacy of each compound,
decontaminated C. parvum oocysts were added to RPM! containing AAT at
concentrations of 1, 10, 100, and 500 l!g / ml or paromomycin at levels of 150,
300, 600, and 1200 l!g / ml. A 1.0-ml aliquot of each of the resulting mixtures
(10 5 oocysts) was used to inoculate BFTE cell monolayers. To evaluate the
combined effects of AAT and paromomycin, each concentration of AAT was
combined with each level of paromomycin for a total of 16 combined
treatment groups. A mixture of C. parvum oocysts in RPM! alone was used

to inoculate infection control samples. The same concentrations of
compounds, single and combined, were added to BFTE cell monolayers to
assess the effect of the compounds on BFTE cells. Inoculated cells were
maintained in a candlejar environment at 37°C for the initial 24-hr postinoculation period. At 24 hr post-inoculation, cell monolayers were rinsed
with RPMI to remove residual inoculum and either collected or retreated
with the same concentration of compound(s) present in the initial inoculum
and further incubated at 37°C / 5% C02 .
BFTE cell monolayers were collected at 24, 48, 72, and 96 hr postinoculation and fixed 10 min in absolute methanol at room temperature.
Fixed cells were rinsed with 25-mM PBS, stained with Giemsa, and rinsed
with distilled water. Coverslips were mounted (inverted) on glass slides with
a permanent mounting medium and examined by brightfield microscopy (oil
immersion, 1000X). Parasite enumeration was accomplished as described by
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Yang et a!. (1996). In brief, parasites were counted in a single scan across the
diameter of each coverslip (approx 65 high-power fields) and the mean
number of parasites counted in each of the treatment groups was expressed as
a percentage of the mean number of parasites counted in an infection control
group .
Synergistic potential was evaluated by calculating fractional inhibitory
concentration (FIC) indices as described by Berenbaum (1978) and interpreted
according to Allen eta!. (1982) . This method is based on the proportional
relationship between IC 50 values for single and combined treatment groups
and was calculated in this study using the following formula:

ICso of AA Tin combination
FIC

ICso of paromomycin in combination
+

ICso of AAT alone

ICso of paromomycin alone

FIC values were interpreted as follows:
FIC < 0.5
FIC 0.5 - 0.9
FIC 1.0
FIC 1.1- 1.9
FIC

~

2.0

= Significant synergism
= Suggestive of synergism
= Additive effect
Indifference or partial antagonism
Antagonism

The difference between the mean number of parasites counted in
treatment and control groups was compared for statistical significance by
ANOVA (Fisher's PLSD) . Similarly, the mean number of parasites counted
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in combined treatment groups was compared to both single compound
treatment groups and corresponding infection control groups for statistically
significant differences. The 50% inhibitory concentration (IC 50 ) values for
AAT and paromomycin treatment alone, and for combined treatment effects,
were calculated using curve-fitting algorithms in the StatView™ data
analysis program.
The anticryptosporidial effect of AAT on in vitro oocyst infectivity was
concentration dependent and exhibited an inhibitory pattern similar to that
previously reported (Forney et al., 1996b). AAT significantly reduced (P <0.01)

C. parvum infection in BFTE cells at concentrations<:: 1 11g/ ml at 24 hr postinoculation relative to untreated control samples. Serpin activity was
progressively less inhibitory to C. parvum infection with increased postinoculation intervals;<:: 100 11g/ml was required to produce a significant
inhibitory effect (P <0.01) at 96 hr post-inoculation (Fig. 5-2a). The pattern of
decreasing efficacy is further evident in the IC50 values determined for AAT at
each of the post-inoculation sampling periods (Table 5-S).
Paromomycin significantly inhibited (P <0.01) in vitro cryptosporidial
infection at concentrations

~

150 11g/ml at each of the post-inoculation

sampling intervals (Fig. 5-2b) . The inhibitory effect of paromomycin was
concentration dependent and progressively increased with continued
incubation of inoculated cultures. The most potent anticryptosporidial effect
for paromomycin was observed in the 48- to 96-hr post-inoculation intervals
and, at 1200 11g/ml, paromomycin consistently reduced parasite numbers
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>90% relative to infection control samples. As seen in Table 5-5, the IC 50
values determined for paromomycin decreased with extended postinoculation sampling intervals.
The combined application of AAT and paromomycin in an oocyst
inoculum significantly inhibited (P <0.01) C. parvum infection at each of the
combinations and post-inoculation sampling intervals monitored in this
study (Fig. 5-3). The inhibitory effect of combined treatment was
concentration-dependent at the 24- to 48-hr post-inoculation sampling
intervals. The contributory effect of AAT concentration was Jess evident in
the latter sampling periods, consistent with the diminished
anticryptosporidial potency noted for the serpin in single compound
treatment groups at 72 and 96 hr post-inoculation.
FIC indices were calculated for combined treatment groups to evaluate
the potential synergistic response of the 2 compounds relative to single
treatment efficacy. The mean FIC value for combined treatment groups at 24hr post-inoculation was 0.1835 , indicating a significant synergistic interaction
for the combination of AAT and paromomycin. Mean FIC values increased
with longer incubation intervals, but continued to fall in a range indicative of
synergistic activity despite the relative decrease in the anticryptosporidial
contribution of AAT (Table 5-1).
The present study is the first to demonstrate a synergistic
anticryptosporidial effect for the combination of a serine protease inhibitor
and an aminoglycoside. While both AA T and paromomycin have previously
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been reported to reduce in vitro C. parvum infection, the findings presented

here show an enhanced inhibitory effect was achieved when oocysts were
simultaneously exposed to these 2 compounds at the time of inoculation.
Further, these data illustrate the potential for a chemotherapeutic strategy to
control cryptosporidiosis using multiple compounds targeting different
developmental stages of the parasite.
The results of this study are in substantial agreement with previous
studies of the in vitro efficacy of AAT and paromomycin. Human AAT has
been reported to reduce parasite infection in BFTE cells in a concentration and
time-dependent manner (Forney et a!., 1996c). Similarly, a progressive
decrease in the anticryptosporidial activity of AAT was observed with
increased incubation periods. Further, AAT has been shown to exert an
antagonistic effect on C. parvum excystation, putatively altering excystation
dynamics with a subsequent decrease in sporozoite viability.
Consistent with the findings of Marshall and Flanigan (1992),
paromomycin demonstrated a significant inhibitory effect on C. parvum
infection at 24 hr post-inoculation. The mode of action for paromomycin in
reducing C. parvum infection is unknown. In general, aminoglycosides
inhibit protein synthesis at the ribosome level and similar activity has been
proposed for the inhibitory effect of paromomycin on in vitro Giardia Iamblia
infection (Edlind, 1989). Rehg (1994) evaluated 6 different aminoglycoside
compounds for anticryptosporidial activity in an immunosuppressed rat
model and found that only paromomycin exhibited a significant inhibitory
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effect on C. parvum infection. The observation that paromomycin is
particularly effective against intermediate stages of C. parvum suggests that
the compound may preferentially target protein synthesis associated with
proliferative asexual development.
The use of multi-compound protocols is a clinically relevant strategy
for treating microbial infections. Combined drug therapy has the advantage
of reducing toxicity by obtaining an effective response at lower concentrations
and may delay the development of drug resistance. In the present study, the
combination of 2 compounds putatively active against different
developmental stages of C. parvum demonstrated the potential to exploit
individual anticryptosporidial activities to facilitate an enhanced inhibitory
response.
In summary, we have demonstrated that AAT and paromomycin can
be used in combination to significantly reduce in vitro cryptosporidial
infection. Using the criteria of FIC indices, we have shown a synergistic effect
for this multi-compound combination in BFTE cell culture. It is readily
acknowledged that in vitro activity is not a universal indicator of analogous
in vivo success and caution is warranted in the extrapolation of results based
solely on in vitro assays. Further studies of the efficacy, toxicity, and systemic
effects of multi-compound treatments in an appropriate experimental in vivo
model are needed to better elucidate their potential therapeutic utility. The
findings presented here demonstrate the capability to achieve a marked
reduction in C. parvum infection and may constitute an alternative approach
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to conventional single-agent treatment protocols. The present study supports

the continued evaluation of multi-agent combinations for enhanced
anticryptosporidial activity and suggests exciting possibilities for future
investigative efforts.
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Table 5-l. Effect of selected protease inhibitors on Cryptosporidium parvum infection of
bovine fallopian tube epithelial cells.

.

%of Control
[PI]t
0

AAT

Aprotinin
100

Leu pep tin

SBTI

MAAPVCK

Anti pain

5

100
49.1± 3.78§

83.9± 6.56t

89.1± 5.41

100.3± 4.25

95.2± 3.68

10

43.9±4.21§

54.2±5.99§

64.8±11.98t

95.9± 7.34

91.8± 5.23

53.11±5.78§

50

42.7± 1.62§

36.1±4.72§

70.2± 4.25t

79.2±13.65

100

30.4± 1.8~

16.8± 5.13§

58.7±11.21 t
51.9± 4.64§

42.13±6.14§

68.3±11.59t

80.2±19.09

20.94±2.16§

500

14.7± 6.31§

10.9±4.71§

43.4± 6.5~

50.5± 2.71§

77.5± 9.69

15.58±1.44§

100

100

100

100
67.74±7.15§

·Mean number of parasites counted per treatment group expressed as a percent± SO of the
mean number of parasites counted in the infection control group; alpha-1-antitrypsin
(AAT}, soybean trypsin inhibitor (SBTI), methoxysuccinyl-ala-ala-pro-valine
chloromethylketone (MAAPVCK) .
t [PI] = Protease inhibitor concentration (~tg/ml) in RPM! medium used in the BFTE cell
inoculum.
tsignificantly different from control group mean at P < 0.01.
§Significantly different from control group mean at P < 0.001.
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Table 5-2. Effect of phenylmethylsulfonyl fluoride on Cryptosporidium

parvum infection of bovine fallopian tube epithelial cells.

[PMSF]
OmM

% of Controlt

1mM

100
68.9± 5.23t

2mM

55.9± 4.67t

3mM

40.0± 8.34§

[PMSF] = Phenylmethylsulfonyl fluoride concentration (mM) in
RPMl medium used in the BFTE cell inoculum.
tMean number of parasites counted per treatment group expressed as a
percent± SO of the mean number of parasites counted in the
infection control group.
+significantly different from control group mean at P < 0.01.
§Significantly different from control group mean at P < 0.001.
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Table 5-3. Effect of alpha-1-antitrypsin on Cryptosporidium parvum oocyst
excystation at 37°C.

% Excystation+

[AAT(

30

10

16.5±2.4
5.2±1.1 t

100

3.2±1.8t

500

1.8±0.7t

0

27.5±4.1

60

90

54.5± 8.9 68.5±11.2

120
74.5± 9.8

180
77.1±10.6

18.5±4.4* 45.5±10.0 52.2±12.7 69.9±14.6 72.1±14.2
9.5±2.1t 39.7±11.8t 57.5±14.4* 64.5± 9.8t 69.6±12.7
8.2±1.2t 19.8± 6.2t 32.3± 8.7t 40.8±10.2t 52.5±13.2*

'concentration in ~-Lg /ml
+Time (min) of incubation
*significant at (P<0.05), mean ± SD
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Table 5-4. Effect of alpha-1-antitrypsin on Cryptosporidium parvum infection
in BFTE cells.

[AAT(
0

10
100
500
1000

·concentration in Jlg/ml
tsignificant at (P<O.Ol), mean ± SO

% of Infection Control Group

100

48.1 ± 6.8zt
36.8 ± 3.s8t
18.3 ± 7.18t
4.6 ± 2.21t
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Table 5-S. In vitro anticryptosporidial activity of alpha-1-antitrypsin and
paromomycin in single and combined treatment groups

Post-inoculation interval (hr)
Treatment"

48

72

96

10.2 ± 2.8

26.3 ± 9.8

466.8±52.6

494.6± 75.9

262.7 ± 33.4

128.2 ± 9.1

80.6 ± 12.4

73.4 ± 9.5

AA Tt
Paromomycin*

AAT + Paromomycin§

0.1835

0.3781

0.7895

0.8571

"Treatment applied at the time of cell culture inoculation.
tDenotes time (hr) post-inoculation.
:!:values represent mean concentration (J.Lg / ml) ± SD (duplicate samples)
capable of reducing parasite infection to 50% of mean control value (IC50 ).
§Values represent mean fractional inhibitory concentration (FIC) indices.
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Figure 5-1. Effect of protease inhibitors on infection of bovine fallopian tube
epithelial cell monolayers by Cryptosporidium parvum oocysts. Data reflect
the mean number of parasites counted at 24 hr postinoculation, expressed as a
percent of the infection control mean, following treatment with alpha-1antitrypsin (-D-), antipain (-A-), and aprotinin (-e -). Error bars represent 1
SD about group means.

146
Fig. 5-2a
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Figure 5-2. Single compound treatment effect on Cryptosporidium parvum
infection in BFTE cells using alpha-1-antitrypsin or paromomycin. Values
represent infection mean± SD for duplicate samples in 2 separate
experiments using (a) AAT or (b) paromomycin. Sampling intervals were
conducted at 24 hr (-•-), 48 hr (-0-), 72 hr (-0 -), and 96 hr (-e-).
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Fig. 5-3a

Fig. 5-3b

Fig. 5-3c

Fig. 5-3d

Figure 5-3. Effects of alpha-1-antitrypsin and paromomycin concentrations in
combined treatment groups. Infection values for (a) 24, (b) 48, (c) 72, and (d)
96 hr post-inoculation sampling intervals. Data reflects mean values for
treatment groups expressed as a percent of untreated control samples
(duplicate samples) from a typical experiment. Replicate experiments
produced similar effects.
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CHAPTER 6
SUMMARY AND CONCLUSIONS

The studies presented herein provide unequivocal evidence of the
recognition and functional interaction of AAT with a component of C.

parvum, putatively expressing serine protease-like activity during
excystation. The biological significance of the observed serpin:parasite
interaction is a potent antagonistic effect on oocyst excystation with a
concomitant reduction in cryptosporidial infectivity in a permissive cell
culture system. It is readily apparent from these studies that the alteration of
the early infection dynamics of C. parvum, in particular the interval
encompassing excystation and initial host cell attachment, has a substantial
inhibitory effect on parasite infection.
The antagonistic role of AAT in inhibiting excystation is attributed to
the functional specificity of the serpin molecule for the active site of serine
protease enzymes. Immunolocalization of SEC interactions on the
membrane of excysted C. parvum sporozoites suggests the expression of a
cognate target enzyme on this early developmental stage of the parasite.
Further, the ability to block AAT recognition of C. parvum with porcine
pancreatic elastase substantiates the specificity of the interaction and
demonstrates a functional capacity for serpin activity in mediating the
biological activity of the invasive sporozoite.
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Select serine protease inhibitors (i.e., PMSF, SBTI, AA T, and aprotinin)
and serine/cysteine inhibitors (i.e., leupeptin and antipain) showed potent
anticryptosporidial potential in preventing infection in cultured epithelial
cells. Further characterization of the anticryptosporidial activity of AAT
showed a significant reduction in C. parvum infection in BFTE cells at 24-48
hr post-inoculation, but the inhibitory effect of this serpin diminished with
continue incubation intervals ranging from 72 to 96 hr post-inoculation.
Similarly, AAT had very little effect on established in vitro infections,
suggesting a minimal impact on developmental intermediates of the parasite.
The differential antagonistic capability of AAT on oocyst excystation
was restricted to oocysts that had been subjected to treatments known to
increase the permeability of the oocyst wall (i.e., bleach decontamination,
incubation in an acidic medium, exposure to deoxycholic acid); entry of AAT
into the intraoocyst milieu required at least partial degradation of the oocyst
wall. The excystation of CsCl-purified oocysts not otherwise subjected to any
permeability-enhancing chemical pretreatments was not significantly
inhibited by AAT. Rather than consigning the role of AAT in antagonizing
excystation as "limited" in terms of its applicability to permeabilized oocysts,
it is more accurate to view the association as physiologically relevant in light
of the progressive passage of oocysts through the digestive system following
ingestion. The biochemical analogy to gut passage and excystation in the
lumen of the small intestine (i.e., acidification, neutralization, exposure to
bile extracts and emulsifying agents) facilitates oocyst excystation and,
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ultimately, enhances parasite vulnerability to serpin-mediated reduction in
excystation efficiency. The effect of serine protease inhibitors on the
excystation dynamics of thin-walled oocysts has yet to be evaluated; the
assumed role of this type of oocyst in perpetuating chronic infection in
susceptible hosts suggests a particularly interesting study for future
consideration.
A curious characteristic of AAT's antagonistic effect on excystation was
the progressive loss of inhibitory potential with increased incubation
intervals. The half-life of AAT in human circulation is in the range of 3-5
days in the noninflammatory state; degradative capacity secondary to a
reduced half-life does not seem to be a plausible explanation for the decreased
inhibitory effect AAT had on excystation at 2- to 3-hr incubation intervals.
One possible explanation for the time-dependent loss of efficacy is the
consumptive nature of the serpin interaction. The serpin molecule binds
covalently to a cognate target enzyme and remains bound, under physiologic
conditions of the human system, until cleared from circulation. In effect,
AA T is a "suicidal" inhibitor. Alternatively, C. parvum may possess
mechanisms to counter serpin activity and, therefore, reduce the inhibitory
capacity of the serpin. The reported ability of cysteine proteases to cleave the
reactive site loop of the AA T molecule suggests a mechanism to rapidly
degrade the molecule's ability to recognize and complex with proteases. This
latter mechanism has been reported to enhance the pathogenicity of bacteria,
and the putative identification of cysteine protease activity in C. parvum
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suggests that studies evaluating degradation of AAT may be of interest in
characterizing parasite defense mechanisms to acute phase proteins such as
AAT.
The transient nature of AAT effects on excystation was a consistent
feature of the studies reported here; continued incubation of AAT-treated
oocysts at 37°C typically produced excystation yields approaching
approximately 65-80% of control group mean values. Despite the relative
increase in excystation with continued incubation, it is noteworthy that oocyst
inoculum containing AA T had significantly lower infection levels in the
early post-inoculation treatment groups. The viability of emerging
sporozoites appears to be directly related to the time interval between the
induction of excystation-related activity and final escape from the oocyst wall.
Specifically, the time lapse between the initial activation of excystation and
the availability of susceptible host cells is a critical factor in C. parvum
infectivity. Sporozoite viability appears to be relatively intolerant of delayed
excystation and a significant loss in infectivity is evident in AAT-treated
oocysts. It is likely that the invasion process (i.e., from excystation to
formation of the parasitophorous vacuole) is dependent upon preexisting
energy stores within the sporozoite; failure to find an obligatory host cell
shortly after emergence is detrimental to infectivity. Though speculative at
present, the implications of the results presented herein suggest that not only
is excystation induced by an activation of enzymatic processes, but once
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activated, bioenergetic demand may be the most critical limitation of
sporozoite viability.
On the basis of the results present here, it is concluded that AAT
antagonizes C. parvum excystation by gaining direct assess to sequestered
sporozoites; some degree of enhanced oocyst wall permeability is necessary for
AAT to inhibit excystation. Further, it is apparent that sporozoite activation
within the intact oocyst wall includes, at least in part, the expression of
proteolytic enzyme activity. It is the association of proteolytic enzyme activity
with excystation, and the functional specificity of the AAT molecule for the
active site of serine proteases, that provides the most likely mechanism for
serpin-mediated inhibition. The alteration in excystation dynamics caused by
AA T accounts for its anticryptosporidial activity against in vitro infection,
putatively by altering endogenous proteolytic activity within the otherwise
intact oocyst.
In an attempt to compensate for the waning efficacy of AAT with

continued post-inoculation intervals, a multiple compound treatment
strategy was evaluated. A study was designed to exploit the
anticryptosporidial efficacy of 2 compounds that theoretically targeted
different stages in the parasite's life cycle. AAT, an apparent excystation
antagonist, and paromomycin, reportedly effective against asexual
intermediates (i.e., type I and II meronts), were applied both individually and
in combination in an in vitro test system. The combined serpinaminoglycoside activities exhibited a potent anticryptosporidial effect in the
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BFTE cell culture system. Further, using the criteria of FIC indices, the study
demonstrated that a significant synergistic response was achieved.
The therapeutic application of protease inhibitors in the treatment and
prevention of human cryptosporidiosis is premature; considerable research is
necessary to better understand the systemic effects of exogenous inhibitors.
The results presented in this dissertation demonstrate a potent antiparasitic
effect for select protease inhibitors in the absence of observed cytotoxicity. The
exact nature of excystation antagonism remains to be fully described;
however, it is likely related to serpin activity on one or more cryptosporidial
serine proteases requisite to proteolytically enhanced modification of the
oocyst wall that facilitates full emergence of the infective sporozoite.
Isolation and characterization of the protease(s) associated with excystation
will provide a definitive answer to the hypothetical significance of enzyme
activity in excystation and invasion of epithelial cells.
While proteases certainly provide opportune targets for antimicrobial
intervention, full therapeutic utility of protease inhibitors in the treatment of
cryptosporidiosis will likely require the development of synthetic inhibitors
with a substantial degree of parasite specificity. This approach is best
illustrated by the recent inclusion of synthetic protease inhibitors in antiviral
protocols for the treatment of HIV infection in humans. Clinical application
of protease inhibitors and substrates as anticryptosporidial agents is
dependent upon demonstrating the relevance of targeted proteases to
infection and the vulnerability of these targets to chemotherapeutic agents. It
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is, therefore, essential that cryptosporidial proteases be isolated and
characterized to include a thorough description of their function in the
parasite's life-cycle.
The collective contribution of these assembled manuscripts is a solid
foundation for future efforts to characterize the structural detail of
cryptosporidial proteases related to excystation and early infection dynamics.
Protein sequence data and homology comparisons to previously described
proteases, both protozoan and mammalian, will provide researchers with a
defined target and enhance the potential for effective clinical intervention.
Inhibition of protease activity is a scientifically and clinically proven method
for preventing infection and ameliorating the pathology associated with
infectious disease processes. The further application of this strategy directed
against parasitic infection is a logical extension of existing scientific and
medical achievement and potentiates the development of a potent arsenal of
novel anticryptosporidial compounds.
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